分類: ACN Newswire

HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - Liuzhou, a key industrial hub in Southwest China, has long been a pioneer in China's industrial history. From manufacturing Guangxi's first automobile and aircraft before the founding of the People's Republic of China to becoming the second-largest industrial city in South China during the reform era, Liuzhou has consistently thrived with the times.Today, as Chinese automotive companies expand globally, Liuzhou's businesses are once again at the forefront, with Wuling Motors (0305.HK) serving as a prominent example.On August 22, Wuling Motors announced its interim results for 2024, demonstrating strong performance across its three main business segments. The company is actively enhancing its high-quality production capabilities and exploring growth opportunities abroad, achieving impressive results in its international ventures.In the first half of 2024, Wuling Motors made significant strides in its overseas expansion: exporting auto parts to Vietnam, golf carts to Egypt, and new energy logistics vehicles to South Korea, as well as establishing a research and development center in Hong Kong...Wuling Motors is sending a clear message to the world: The company's future is bright, with limitless potential.(I) Moderate Growth in Auto Parts and Other Industrial Services RevenueAccording to Wuling Motors' 2024 interim report, the company achieved a revenue of CNY 3.946 billion in the first half of this year, with a gross profit of CNY 426 million. Net profit surged 72.3% to CNY 21.125 million compared to the same period last year.Breaking down the segments, the auto parts and other industrial services business recorded a revenue of CNY 2.698 billion in the first half of the year, up 6.1% year-on-year. During this period, Wuling Motors focused on consolidating its existing market while aggressively expanding into new territories. The company aimed to break into growth markets dominated by giants like Great Wall Motors, Chery, and BYD. Sales to newly acquired customers surged to CNY 1.042 billion, accounting for 38.6% of the divisional revenue.Wuling's Jingmen base in Hubei, dedicated to supplying Great Wall Motors, rapidly scaled up its production, generating CNY 334 million in revenue in the first half of the year. It successfully delivered frame assemblies for two Great Wall models, breaking the record for the highest first-month delivery of a new product. Additionally, Wuling's domestic ultra-high-strength steel tube hydroforming production line - a first in China - successfully commenced mass production, supplying 13 hydroformed products to premium models from brands like Great Wall and BYD.The auto parts and other industrial services segment posted an operating profit of CNY 75.883 million in the first half of the year, up 44.3% year-on-year.In the automotive power systems segment, Wuling Motors achieved CNY 902 million in revenue. While strengthening its traditional power technology upgrades, Wuling Motors accelerated its layout of new energy power integration development, speeding up its new energy business initiatives. In the first half of 2024, Wuling accelerated the establishment of a comprehensive product matrix for hybrid and battery electric powertrains and core components, advancing production capacity and rolling out new products and technologies. By promoting its products, Wuling Motors has focused on building lines and improving processes for motors, motor controllers, rotors, and stators, securing new energy market collaborations with JAC Motors and Changan Kaicene.The commercial vehicle segment posted CNY 331 million in revenue in the first half of the year, primarily seeking breakthroughs in high-value-added sub-sectors.Wuling Motors achieved a gross profit margin of 10.8% in the first half of 2024, a significant increase of 270 basis points from 8.1% in the same period in 2023. This impressive growth was largely driven by declining prices for raw materials, such as steel. Additionally, the ramp-up of higher-margin products further contributed to the substantial improvement in the company's profitability.(II) Striking the Main Chord of Overseas ExpansionIn the 1960s and 1970s, Liuzhou's tractors were exported to Vietnam and Rwanda in Africa, and in 1990, its microcars were shipped to Thailand. Liuzhou-made vehicles have consistently ventured overseas.Today, Liuzhou's automotive industry faces another historic opportunity for overseas expansion.As domestic market demand becomes saturated, expanding abroad has become essential for Chinese companies, and overseas markets are emerging as the new "blue ocean."For example, Guangxi's exports were robust in the first half of the year. According to customs statistics, Guangxi's import and export trade reached CNY 345.28 billion in the first half of 2024, up 12% year-on-year. Exports alone hit CNY 191.8 billion, a record high, rising 28.5%. Exports of major categories like mechanical and electrical products and labor-intensive products were CNY 109.18 billion and CNY 37.3 billion, respectively, growing by 26.8% and 48.5% and accounting for 56.9% and 19.4% of Guangxi's total exports.In the automotive market, "intense competition" and "overseas expansion" are the current hot topics. According to the China Association of Automobile Manufacturers (CAAM), in July 2024, China exported 469,000 vehicles, up 19.6% year-on-year. From January to July 2024, China's auto exports reached 3.262 million units, up 28.8%. Among these, exports of battery electric vehicles totaled 554,000 units, and plug-in hybrid vehicles reached 154,000 units, representing a 180% increase year-on-year.Specifically in Liuzhou, more than 90,000 vehicles were exported through Liuzhou Customs in the first half, up 23.8% year-on-year; of these, over 10,000 were new energy vehicles (NEVs), a surge of more than 30-fold.Wuling Motors has seized this trend, charting a course for global success.Take the Wuling golf cart as an example. With its strong handling, lightweight design, comfortable ride, and powerful performance, the Wuling golf cart has been highly favored by overseas customers. Since its launch, it has been sold in countries across Southeast Asia, Central Asia, Europe, and America.Earlier this year, Wuling Industrial, a subsidiary of Wuling Motors, showcased its new multi-purpose golf/community vehicles at the 71st PGA Merchandise Show in Orlando, USA, drawing significant attention. On April 15, the 135th Canton Fair kicked off in Guangzhou, where Wuling Industrial's golf carts attracted buyers from 205 countries and regions worldwide. On May 22, Wuling Industrial shipped about 200 golf carts to Egypt, expecting to complete delivery in the third quarter.Wuling Motors' joint venture, Wuling New Energy, also broke new ground with its G050 left-hand drive battery electric logistics vehicle. In March 2024, the company secured its first order of 300 units with South Korea's Daechang Corp, marking a breakthrough in the Korean market.Currently, Wuling's sightseeing vehicles, golf carts, and other products are exported to countries such as Vietnam, Singapore, Thailand, the USA, and Australia. Its new energy logistics vehicles have also penetrated traditional automotive powerhouses or regions such as the USA, Japan, and Europe, laying a solid foundation for expanding into the international market.This achievement is due to Wuling Motors' strategic planning.In recent years, Wuling Motors has accelerated its overseas expansion, with subsidiaries in India and Indonesia continuing to strengthen their presence. These efforts, focused on promoting the localization and launch of new models with key clients, have proven highly effective, helping Wuling penetrate new customer bases and meet international standards.On the product side, Wuling Motors has further enriched its product lineup, with more auto parts poised to enter global markets. In a major breakthrough, Wuling's self-developed rear drive axle assembly and drive system assembly for new energy passenger vehicles successfully entered the overseas market in the first half of this year. This achievement marks a departure from the traditional three-section axle housing structure, instead adopting a hydraulic expansion integral axle housing technology, which has been well-received by customers. On the channel side, Wuling is leveraging Hong Kong as an export conduit for its new energy business, boosting overseas sales for the group and its joint ventures.On the research and development front, Wuling Motors has established an innovation center in Hong Kong and signed memoranda of understanding (MOUs) with Hong Kong Polytechnic University (PolyU) and the Chinese University of Hong Kong (CUHK) to focus on NEV technology, jointly promoting the conversion and application of scientific research results.(III) Driving Global Growth Through High-Quality ProductionIn global competition, technology reigns supreme. Wuling Motors has been a pioneer in the NEV sector, steadfastly pursuing the development of NEVs. With a goal of deriving more than 50% of its business from NEV operations, Wuling is laying a solid foundation to become a front-runner in the new energy vehicle era as it ventures into overseas markets.In the auto parts business, Wuling Motors continues to align with the "passenger-focused" and "electrification" upgrades of its customers' products, continuously developing passenger vehicle products while actively supporting new energy vehicle models for major customers.Currently, Wuling Motors has successfully developed and optimized a range of products, including new energy electric rear axles, motors, motor controllers, range extenders, and hybrid systems. This year, the production of core components such as electric axles and hybrid engines has seen steady growth.After surpassing the milestone of producing one million units of micro electric axles, Wuling's coaxial electric drive axle became the first to achieve commercialization in China. It has been adopted by brands such as Changan Kaicene, Ruichi, and JAC Motors. Wuling Motors also secured orders from leading companies like Chery and Geely for electric axles used in mainstream NEV commercial vehicles. At Wuling's Jingmen base, which supplies auto parts to Great Wall Motors, business has flourished, with over 50% of its products sold in the first half of 2024 being NEV parts, generating CNY 333 million in revenue.In automotive power systems, Wuling Motors has made remarkable progress in developing and mass-producing high-efficiency engines and new energy power systems. Their strategy seamlessly integrates traditional power technology upgrades with new energy power innovations, resulting in a robust product lineup. In the first half of 2024, Wuling Motors focused on enhancing production lines and processes for motors, motor controllers, and rotors and stators. The H-platform ultra-high-efficiency engine has been successfully commercialized, securing projects with NEV clients like JAC, Changan, and Skyworth. Additionally, Wuling's casting sales reached 515,000 units, up 26.2% compared to the same period in 2023.In the commercial vehicle segment, Wuling focuses on specialized modification markets such as cold chain vehicles, sanitation vehicles, and medical vehicles. Their specialty products, including refrigerated trucks, sanitation trucks, and fire trucks, have been delivered to regions like Shandong, Zhejiang, Hunan, and Beijing. Leveraging its customization capabilities, Wuling has partnered with PepsiCo to develop a "mobile new retail" model, delivering over 100 Wuling vending trucks to PepsiCo and accelerating the expansion of mobile commerce.Wuling's joint venture, Wuling New Energy, is actively upgrading its brand and market position. They launched the long-range Golden Storage Mid-size Logistics Vehicle to quickly capture market share, achieving monthly sales exceeding 1,000 units in the first three months after launch. Additionally, Wuling New Energy is aggressively expanding into international markets, increasing exports to countries such as the USA, Japan, and South Korea. In the first half of 2024, Wuling New Energy sold approximately 7,900 NEVs, a 68.1% increase compared to the same period in 2023.It is evident that Wuling Motors' strategic direction is becoming increasingly clear.With a comprehensive business layout and a full range of products, Wuling has created synergies across its industrial chain, positioning itself as Guangxi's most comprehensive leading automotive group in the supply chain. With unparalleled control over product quality, cost, scale, and customer relations, Wuling has built a formidable competitive advantage.As the NEV era rapidly approaches, Wuling Motors is fortifying its dominant businesses, focusing on high-tech, competitive, and high-end flagship auto parts, expanding markets for high-value specialized modified vehicles, and advancing its NEV key parts and vehicle business.With these foundations, Wuling is boldly venturing overseas, aiming for growth through globalization and efficiency in management, poised for even higher-quality development in the new era. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com)  Beijing Tong Ren Tang Chinese Medicine Company Limited (“Tong Ren Tang Chinese Medicine” or the “Company”, Stock code: 3613.HK) is pleased to announce the unaudited results of the Company and its subsidiaries (collectively referred to as the “Group”) for the six months ended 30 June 2024 (the “Period”).In the first half of 2024, facing challenges such as the sustained strength of the Hong Kong dollar, changing consumption patterns, and a sluggish retail industry in Hong Kong, China and Macau, China regions, the Group responded proactively and made simultaneous efforts from multiple dimensions of products, marketing, research and development, and production. This ensured the stable operation of its business and the continued consolidation of its market-leading position. During the Period, the Group achieved revenue of HK$ 664.5 million, net profit of HK$ 240.3 million, and profit attributable to owners of HK$ 219.8 million, with earnings per share of HK$ 0.26.By market segment, during the Period, the Group further enriched its product matrix and optimized its retail market layout. The Hong Kong, China market achieved revenue of HK$333.8 million, with 30 retail terminals, a net increase of 3 terminals compared with the previous year. In the markets outside Mainland China (excluding Hong Kong, China,), the Group accelerated its brand market expansion and steadily promoted its internationalization, achieving revenue of HK$214.4 million. In addition, the Group achieved revenue of HK$116.3 million in Mainland China market.Sufficient momentum from technological innovation, new breakthroughs in production and R&DThe development of science and technology has provided new technical support and growth strategies for the advancement of traditional Chinese medicine (“TCM”). During the Period, the Group leveraged technological innovation as a driving force, empowering intelligent upgrades in production and enhancing product excellence and innovation. This has helped accumulate new momentum for future growth and supported the inheritance and innovation of TCM.Product quality is the lifeline of an enterprise. At the production level, the Group’s production and R&D base in Tai Po consistently upholds stringent standards and rigorous procedural controls. The Group has successfully secured Hong Kong, China’s GMP and ISO22000 certifications, with its product quality has been recognized. Additionally, to further enhance the cost competitiveness of its products, the Group has intensified efforts in revamping and upgrading its production layout. By increasing mechanization and automation, the Gorup has effectively reduced production costs and boosted productivity, thereby ensuring consistent product availability in the market.In terms of products, the Group intensifies its R&D efforts, actively diversifying its product matrix and expediting the translation of scientific research outcomes. During the Period, the Group completed the production of a number of new registered proprietary Chinese medicines and health food products, including Guizhi Fuling Wan , Lingzhi Turmeric Compound Blood-supplementing and Nerve-calming Capsules , Wolfberry Coffee Mix , Red Ginseng Coffee Mix  and Sporoderm-broken Ganoderma Lucidum Spores Chocolate . The Group also plans to commence the production of Qiyao Pills ) and Jinshui Liujun Jian Granules. In April this year, the Group’s self-developed product, Danggui Buxue Keli, were awarded the Certificate of Registration of Proprietary Chinese Medicines (HKC-18604) issued by the Chinese Medicine Council of Hong Kong, China, further enriching the Group’s product portfolio. In May this year, the Group’s invention patent (Patent Number: ZL 2023 1 1206874.8) for “a freckle-removing and whitening product along with its preparation method and uses was successfully granted by China National Intellectual Property Administration and has been applied to Ageing-Defying Collection of the Tong Ren Tang’s Chinese anti-aging NMN series.In addition to preserving and advancing TCM services, the Group is also expanding into new health concept areas. During the Period, the Group entered into a Memorandum of Understanding with Deer Industry New Zealand to promote innovative health-functional deer food products, assisting both parties in collaborative development, registration and marketing efforts. The Group will give full play to strengths in both its proprietary brand and Chinese medicine, combined with the resource advantages provided by New Zealand, the origin of deer velvet, to accelerate the R&D of New Zealand deer products and the deployment of the industrial chain configuration, and continue to expand into new health domains.Moving forward, the Group will continue to strengthen its cooperation with internationally renowned institutions and research organizations such as the University of Hong Kong, Hong Kong Baptist University and the University of California, to conduct research on the safety and mechanism of key products such as Tong Ren Tang’s Angong Niuhuang Wan , Ganoderma Lucidum-related products and Tong Ren Niu Huang Qing Xin Wan, in order to further expand its scientific research results, and to provide a reliable scientific basis for the entry of its products into the mainstream markets overseas in the future. The Group adheres to the highest standards of superior, pure and genuine traditional Chinese medicinal materials, and brings together the essence of the intangible cultural heritage culture and exquisite craftsmanship, as well as strict and meticulous production to fully embody the Group’s motto: “Never cut corners on labour and quality, no matter how complex the process or how costly the materials”. This philosophy not only enhances the health value delivered to customers but also provides the Group with a stronger growth momentum.Orderly market expansion and diversified marketing to strengthen brand effectIn terms of market expansion, on the one hand, the Group has continuously introduced new products to consolidate and expand its market share. During the Period, the Group launched new products, including the Tong Ren Tang’s Chinese anti-aging NMN series – the Youth Prime Collection  and the Age-Defying Collection, the Guizhi Fuling Wan , and Wood Lok Medicated Oil , broadening its product range. At the same time, the Group further expanded its retail presence in Hong Kong, China by opening three new retail outlets in North Point, Mong Kok, and West Kowloon. The North Point and West Kowloon stores also offer Chinese medical consultation and treatments to reach a wider customer base.In terms of product marketing, the Group has intensified its marketing efforts to increase product recognition. Specifically targeting the “major variety” products, such as Tong Ren Tang Angong Niuhuang Wan and Sporoderm-broken Ganoderma Lucidum Spores Powder Capsule and Tong Ren Niu Huang Qing Xin Wan, the Group promoted and advertised the brand and products through an omni-channel approach, integrating special festivals and themes to create consumer hotspots. Moreover, the Group has also advanced the development of both online and offline channels, continuously expanding its sales channels to meet the demands of post-pandemic era business models.In terms of brand promotion, the Group capitalized on its participation in major events, significantly enhancing its promotional efforts and accelerating the brand market expansion. During the Period, serving as a critical portal for Beijing Tong Ren Tang’s international development, the Group participated in the 2024 Wuzhen Health Conference, showcasing its flagship products and a variety of new products. In implementing the “Belt and Road” initiative, the Group leads time-honored brands venture into the world and integrates into the international arena. By adopting the “bring in” and “go global” strategy, the Group is promoting the rich and profound TCM culture, further disseminates Chinese health wisdom globally to benefit more people.Additionally, the Group has enhanced its brand image and influence through public welfare activities. The Group has actively encouraged its overseas retail outlets that offer Chinese medical consultations and treatments to provide charity Chinese medicine clinic services. This initiative embodies the Group’s philosophy of “introducing medicine through treatments” and supports its brand development. In Hong Kong, China, the Group has fully supported and participated in public welfare activities, demonstrating to society and the public the Group’s corporate spirit of “Nurturing kindness and virtue, preserving tranquility and wellness ”. Through its services and products, the Group is dedicated to deeply embedding the Tong Ren Tang brand, products and Chinese medical consultation and treatments services into the community, spreading the culture of Tong Ren Tang while encouraging a healthy lifestyle among community residents.Future ProspectsWith the ongoing economic and social development, an intensifying aging population trend, and the increasing health awareness among residents, the pharmaceutical consumption market is expected to expand continuously. TCM, as a crucial sector of the pharmaceutical industry, continues to hold significant potential for growth in the global market.In the future, the Group will continue to strengthen R&D efforts and expand its proprietary product matrix, including products such as Ganoderma Lucidum series and anti-aging series, to create diversified growth engines and drive the realization of high-quality developmental transformation within the Group. At the same time, the Group will focus on business development by enhancing its new retail layout, accelerating the introduction of new products, continuously advancing the registration of Tong Ren Tang’s key products in Vietnam, innovating business models, and reinforcing its core competitive advantages. By leveraging the development of new quality productive forces as its engine, the Group strives to achieve sustained growth in its business scale. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年8月30日 - (亞太商訊 via SeaPRwire.com) — 北京同仁堂國藥有限公司（「同仁堂國藥」或「公司」，股份代號：3613.HK）欣然公佈公司及其附屬公司（統稱為「集團」）截至2024年6月30日止六個月（「本期內」）之未經審計業績。2024年上半年，面對港元匯率持續高企、消費模式轉變、港澳地區零售業疲弱等挑戰，集團積極應對，從產品、營銷、研發、生產等維度同步發力，保障了業務經營的平穩運行，市場領先地位持續鞏固。本期內，集團實現收入664.5百萬港元，淨利潤240.3百萬港元，擁有人應佔利潤219.8百萬港元，每股盈利0.26港元。分市場來看，本期內，集團進一步充實產品矩陣、優化零售市場佈局，中國香港市場實現收入333.8百萬港元，零售終端達30家，較上年淨增加3家。境外市場（除中國香港市場）方面，集團加速品牌市場拓展，穩步推進國際化進程，取得收入214.4百萬港元。此外，集團於中國內地市場實現收入116.3百萬港元。科技創新動能充足  生產研發再獲新突破科技的發展為中醫藥發展提供了新的技術支撐和發展思路。本期內，集團以科技創新為驅動力，賦能生產的智能化升級以及產品的卓越與創新，為未來發展積蓄新動能，助力中醫藥傳承創新。產品質量是企業的生命線。在生產端，集團大埔生產研發基地始終秉承著嚴謹的作風，嚴格流程管控，順利通過中國香港GMP、ISO22000認證，產品質量獲得認可。此外，為進一步提高產品的成本競爭力，集團加強生產佈局改造升級，提高生產機械化、自動化程度，有效降低生產成本的同時提升產能，保障了產品市場供應。在產品端，集團發力研發，積極豐富產品矩陣，加速科研成果轉化。本期內，集團已完成多款新註冊中成藥及保健食品的生產工作，包括桂枝茯苓丸、靈芝薑黃複方活血安神膠囊、枸杞咖啡、紅參咖啡及破壁靈芝孢子巧克力，亦計劃開展芪藥丸及金水六君煎顆粒的投產工作。今年4月，集團研發的當歸補血顆粒獲取中國香港中醫藥管理委員會頒發的中成藥註冊證書(HKC-18604)，進一步豐富集團的產品組合。今年5月，集團「一種祛斑美白產品及其製備方法、用途」的發明專利（專利號：ZL 2023 1 1206874.8）成功獲得中國國家知識產權局授權，並已應用於同仁堂保齡中式抗衰老NMN系列產品中。在傳承及發展傳統中醫藥服務的同時，集團亦不斷拓展健康概念新領域。本期內，集團與紐西蘭鹿業局簽署關於鹿產品的新型健康功能食品推廣支援的諒解備忘錄，協助雙方合作開發、註冊和銷售工作。集團將充分發掘自體品牌及中藥優勢，結合紐西蘭鹿茸原產地資源優勢，加速紐西蘭鹿產品研發及產業鏈佈局，不斷邁向健康新領域。未來，集團將繼續加強與香港大學、香港浸會大學、美國加州大學等國際知名院校及研究機構的合作，對同仁堂安宮牛黃丸、靈芝類產品及同仁牛黃清心丸等重點品種開展安全性和作用機理等研究，進一步擴大科研成果，為未來產品進入海外主流市場提供可靠的科學依據。集團秉承著更上等、純潔、道地的最高級傳統藥材標準，匯聚非遺文化精粹和精湛工藝，以及嚴格精心製作，充分體現北京同仁堂「炮製雖繁必不敢省人工，品味雖貴必不敢減物力」古訓，為消費者帶來更好的健康價值的同時，也將為集團提供更強大的增長動能。市場拓展有序推進  多元營銷強化品牌效應在市場拓展方面，集團一方面不斷推出新品，鞏固並擴大市場份額。本期内推出同仁堂仙齡、保齡中式抗衰老NMN系列產品、桂枝茯苓丸、活絡油等新產品，產品覆蓋範圍持續拓寬。與此同時，集團亦進一步擴大中國香港零售市場，在中國香港北角、旺角及西九龍共新設三家零售終端，同時北角及西九龍店提供中醫診療服務，以觸達更多消費人群。在產品營銷方面，集團積極加大市場營銷力度，提升產品知名度。特別是針對同仁堂安宮牛黃丸、破壁靈芝孢子粉膠囊及同仁牛黃清心丸等「大品種」產品，集團通過全媒體渠道，進行品牌和產品的推廣及宣傳，同時結合特定節日及主題，打造消費熱點。不僅如此，集團亦積極推進線上及線下渠道的開發，不斷擴充銷售渠道，滿足後疫情時代的商業模式。在品牌宣傳方面，集團充分利用參加大型活動的契機，加大投入宣傳力度，加速品牌市場拓展。本期內，集團作為北京同仁堂國際化發展的重要窗口，參與2024年烏鎮健康大會，展出集團王牌產品及多元化新產品。在積極踐行「一帶一路」倡議的同時，帶領老字號走向世界，融入國際舞台。通過「引進來」「走出去」弘揚博大精深的中醫藥文化，進一步將中國健康智慧傳播至全球，惠及更多人。另外，集團還通過公益活動等方式，提示品牌形象和影響力。在海外，集團積極號召在境外設有中醫診療服務的零售終端，通過開展中醫義診活動，實行「以醫帶藥」，助力品牌發展。在中國香港，集團全力支持及參與社會公益活動，向社會及公眾展示集團「同修仁德，濟世養生」的企業精神。並經由服務及產品，將同仁堂品牌、產品及中醫診療服務深入到社區中，在傳播同仁堂文化的同時，推動社區居民的健康生活方式。未來展望經濟及社會的持續發展、社會人口老齡化趨勢的加劇以及居民健康意識的不斷增強，將驅動醫藥消費市場不斷擴容。中醫藥作為醫藥產業的重要組成部分，在全球市場顯示出巨大的發展潛力。未來，集團將持續加強研發創新，擴大自有產品矩陣，如靈芝產品系列、抗衰老系列產品等等，打造多元化增長引擎，推動實現高質量發展轉型。同時，集團亦專注於業務發展，通過強化新零售佈局、加速新產品上市、持續推動同仁堂重點產品在越南註冊、創新業務模式，強化自身核心競爭優勢，以發展新質生產力為引擎，實現集團業務規模的持續增長。 Copyright 2024 亞太商訊 via SeaPRwire.com.

香港, 2024年8月30日 - (亞太商訊 via SeaPRwire.com) — 8月29日，天津銀行召開2024年中期業績發布會。2024年上半年，天津銀行紮實做好金融「五篇大文章」，賦能「新質生產力」，積極踐行「四個善作善成」重要要求，聚焦「科技創新、產業煥新、城市更新」「盤活存量、培育增量、提升質量」和天津市「十項行動」，深化法人治理，紮實推進「雙五戰役」，實現平穩開局，穩中有進，為全年穩健發展奠定良好基礎。業務經營形勢進一步向好，高質量發展基礎進一步夯實經營規模持續增長。資產總額人民幣8,973.8億元，較上年末增長6.7%，其中貸款余額人民幣4,414.0億元，較上年末增長11.5%。負債總額人民幣8,304.6億元，較上年末增長7.1%，其中存款余額人民幣4,822.2億元，較上年末增長7.0%。收入利潤實現雙增。實現營業收入人民幣87.6億元，同比增長7.7%；實現撥備前利潤人民幣67.4億元，同比增長8.1%；實現凈利潤人民幣19.8億元，每股收益人民幣0.32元。資產質量有效改善。不良貸款率1.54%，較上年末下降0.16個百分點；撥備覆蓋率181.75%，較上年末上升13.89個百分點，風險抵補能力不斷增強。重點著墨「五篇大文章」報告期內，天津銀行已製定「關於做好金融五篇大文章賦能天津高質量發展的實施方案」，協同推進金融「五篇大文章」。搭建科技金融服務體系。作為「科技-產業-金融」新循環試點行，優化科技金融服務模式，整合科技金融產品服務體系，發布「智慧科技通」金融服務方案。科技創新企業貸款余額人民幣144.94億元，較上年末增長24.0%；承銷及投資科創票據人民幣48.5億元；打造天津銀行系列科創成長基金，推廣「一區一基金」模式，三只基金的合作協議已簽署落地。推動綠色金融高質量發展。綠色貸款余額人民幣330.41億元，較上年末增長35.69%，發放天津市首筆「企業綠碼」掛鉤貸款、天津銀行首筆EOD模式項目貸款和首筆可持續發展掛鉤跨境銀團貸款。實現ESG領域債券承銷及投資人民幣81.11億元，在交易商協會2024年上半年綠色債務融資工具投資人排行榜中位列城商行第三位。普惠金融向深向實發展。強化金融科技賦能，豐富產品服務體系，穩步提升普惠金融服務效率和水平。涉農貸款余額人民幣264.27億元，較上年末增長23.55%，「智慧富民通」累計放款人民幣40.77億元，惠及6.53萬農戶。打造「智慧通普惠」數字金融生態服務平臺，聚焦小微企業、個體工商戶，智慧商戶通合作商戶120.53萬戶，較上年末增長21.65%；「智慧商戶通·天行用唄」累計放款人民幣294.01億元，較上年末增長49.88%，從源頭上解決了個體工商戶「融資難、融資慢、融資貴」的難題。打造「金秋港灣」養老金融特色品牌。推出養老金融「專有投資者教育、專屬產品貨架、有溫度的專業服務、專項滿意度調研、專註打造特色網點、專策金融支持」「六專」服務體系，營業網點進一步對標適老服務標準，優化適老金融線上服務渠道，舉辦天津市養老金融暨銀發經濟專題研討交流活動。適老儲蓄產品余額人民幣848.52億元，較上年末增長8.64%；適老理財產品余額人民幣262.01億元，較上年末增長6.71%；第三代社保卡新增激活8.7萬張，網均發卡數量位列天津市第一。深化數字金融助力新質生產力。強化頂層設計，積極踐行數字銀行建設戰略，對外聚焦「服務效能」，對內聚焦「安全生產」，不斷提升一體化運營、多元化數據價值釋放、智慧化服務再造、數智化營銷、綜合化事務支撐及智能化風控等能力。培育數字經營新模式，開啟企業級全渠道客戶數字化運營平臺，通過大數據模型實現獲客、活客和價值轉化能力顯著增強，截至報告期末，實際觸達基礎客戶324.65萬戶，帶動手機銀行新增客戶11.35萬戶，AUM月日均提升人民幣37.60億元。激發數字金融服務新動能，推出全員作戰系統，為戰略部署高效執行和職能部門協同作戰打造新引擎；通過「數看天行」全面展現經營數據，提升拓客和經營決策效能。加速科技成果積澱轉化，年內榮獲鑫智獎「數智化轉型先鋒 企業」等獎項5項，獲批17項知識產權。深入踐行「四個善作善成」重要要求在發展新質生產力上善作善成。發布「聚力新質生產力發展的工作方案」，旨在以金融力量支持新質生產力加快發展。支持現代產業體系，中長期製造業貸款余額人民幣145.28億元，較上年末增長36.23%，12條重點產業鏈貸款余額人民幣30.69億元，較上年末增長33.46%。供應鏈貸款余額人民幣126.95億元，較上年末增長14%，天津地區綠色貸款余額人民幣256.01億元，較上年末增長56.43%。支持科技創新和產業轉化，運用「股、債、貸、基、租、保」多元化接力式的綜合金融服務，加大對天開高教科創園企業和人才的精準支持。支持盤活用好存量資源，累計為天津市資產盤活領域投放信貸資金人民幣385億元。在全面深化改革開放上善作善成。支持建設高水平開放型經濟新體製，聚焦港產城融合發展行動，為濱海新區高質量發展、北方國際航運核心區、「一帶一路」提供金融支持。濱海新區對公貸款投放余額人民幣511.66億元，較上年末增長17.54%；支持京津冀協同發展，京津冀地區貸款余額人民幣3,405.1億元，較上年末增長16.4%；累計承銷及投資京津冀地區各類債券人民幣476.59億元。與武清區、津南區政府及京津冀16家企業簽署戰略合作協議，「京津冀產業交流綜合金融服務平臺」發布上線。在推動文化傳承發展上善作善成。支持科教興市人才強市行動，強化金融與教育領域深度融合，提供貸款融資、智慧校園建設等綜合金融服務。打造「運動金融」品牌，發放馬拉松主題「悅動卡」和專屬理財，理財募集資金已達人民幣7.4億元；「智慧文旅通」「智慧商戶通」助力文旅場景拓展，盤活抵羊、利順德等「老字號、老品牌」，通過商標權、專利權質押的方式為老字號企業提供新增貸款人民幣7.4億元。與佛羅倫薩小鎮商圈簽署戰略合作協議，構建京津冀區域商旅文體農融合特色消費生態圈。將古文化街建設成為天津市「優化支付服務」標桿場景。在提升城市治理現代化水平上善作善成。助力城市更新，製定《支持「中心城區更新提升行動」服務方案》，在城市更新領域提供授信支持人民幣37.3億元。搭建智慧公共服務體系，建設智慧教育通、智慧醫療通，提供全方位的綜合性數字化服務方案，推動城市業態、功能、品質不斷提升。下一步，天津銀行將繼續深入貫徹黨的二十大、二十屆三中全會及中央金融工作會議精神，做好「五篇大文章」，深入踐行「四個善作善成」，落實天津市委市政府「三量」「三新」工作要求，服務天津市「十項行動」，為高質量發展註入推動力支撐力。 Copyright 2024 亞太商訊 via SeaPRwire.com.

HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - On 28 August 2024, Fosun International (HKEX: 0656) announced its 2024 interim results. During the reporting period, its revenue continued to grow, reaching RMB97.84 billion. Industrial operation profit maintained growth, reaching RMB3.47 billion, and profit attributable to owners of the parent was RMB720 million.Guo Guangchang, Chairman of Fosun International, said at the results presentation on the morning of 29 August, “In the first half of the year, although the macro environment remained challenging, we resolutely executed our strategy of focusing on core businesses, developing industry-leading companies and products in the industries where we have formed advantages. Such strategy has been proven effective in general. Looking ahead, we will remain focus on innovation and globalization, while focusing on asset-light operations, driving long-term development with competitive core strengths.”Since the beginning of 2024, the domestic economic recovery has been rocky and the international market has remained volatile, which has brought challenges to Chinese companies including Fosun. Fosun steadfastly pushed forward its strategic focus, driving development with core strengths, achieving quality and efficiency improvement in core industries, and maintaining a solid asset base.Analysts believe that, based on Fosun’s interim results, Fosun’s focus on the core industries in the household consumption sector and its proactive approach to driving innovation and globalization have further reinforced its business foundation, resulting in predictable stable profits. Additionally, over the past two years, Fosun has actively pursued asset-light operations, optimized asset portfolio, and continued to reduce leverage. These efforts have resulted in abundant cash reserves and a stronger financial cushion, which are expected to prompt the market to reassess Fosun’s value.Staying ahead in globalization and innovation, reinforcing business foundation to develop industry-leading companies and products      In the first half of the year, Fosun’s four core subsidiaries, namely Fosun Pharma, Yuyuan, Fosun Insurance Portugal, and Fosun Tourism Group (“FTG”), achieved total revenue of RMB72.17 billion, accounting for 74% of the Group’s total revenue. Fosun’s strategy of focusing on core businesses has shown increasing benefits, with its advantages in core industries such as pharmaceuticals, tourism, consumption, and insurance continue to be strengthened.With years of effort in the aforementioned sectors, Fosun has developed a number of industry-leading companies and products.For example, in the first half of this year, Fosun Pharma, which ranks second among the top 100 pharmaceutical companies in China, was selected as one of top 20 global pharmaceutical companies in terms of pipeline scale for the third consecutive year. Shanghai Henlius is the first Chinese profitable innovative biopharmaceutical company listed in Hong Kong, with multiple independently developed monoclonal antibody biosimilars that are driving the rapid development of China’s biopharmaceutical industry. Its first blockbuster product, HANLIKANG, is the first domestic biosimilar approved for marketing. Fosun Insurance Portugal holds the largest market share in the Portuguese insurance market and ranks among the leaders in the insurance sector across Portuguese-speaking regions globally. Easun Technology, in the intelligent manufacturing segment, is a global leading automation and digitalization company.In addition, in the Happiness business segment, Club Med, a subsidiary of FTG, is the global leader that offers exquisite “all-inclusive” holidays. Atlantis Sanya is the leading integrated high-end tourism destination in China, helping to usher Hainan tourism into the 3.0 era. Laomiao Gold, a subsidiary of Yuyuan, is a China time-honored brand and a nationally renowned jewelry brand. These industry-leading companies and products have helped Fosun consolidate its leading position in related sectors.For Fosun, steady and profitable growth is driven by two factors: innovation and globalization.Amid the current domestic economic “involution”, “going global” has become a “must-do” for businesses. Fosun, which began its globalization journey as early as 2007, has become one of the benchmark global companies rooted in China. It has also established a profound industrial presence in more than 35 countries and regions worldwide.During its 17-year globalization journey, Fosun has achieved many successful projects and faced various challenges. Most importantly, this experience has allowed Fosun to develop globalization capabilities that rare among domestic companies. In addition, it has allowed Fosun to connect different markets, industries, and resources globally, achieving global presence, operations and development, while continuously enhancing its global operation capabilities.This is further illustrated by the following data, the Group’s overseas revenue for the first half of 2024 reached RMB45.87 billion, representing a year-on-year increase of 4%, and accounting for 47% of total revenue. Nearly half of the revenue came from overseas, which is rare among Chinese companies.More importantly, Fosun has actively driven the empowerment and synergy of its corporate ecosystem in the course of globalization. Its domestic and overseas member companies have made significant progress in global research and development (R&D), business expansion, operations, and investment and financing.For example, HANQUYOU, independently developed by Fosun’s subsidiary Shanghai Henlius, received marketing approval from the United States (U.S.) Food and Drug Administration (FDA), making it a “Chinese” monoclonal antibody biosimilar approved in China, the European Union (EU), and the U.S. HANLIKANG, China’s first biosimilar, received marketing approval from the Peruvian General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru, making it the third self-developed drug of Shanghai Henlius to be approved for overseas marketing after HANQUYOU and HANSIZHUANG.Moreover, Club Med, a subsidiary of FTG that operates 67 resorts worldwide, achieved a record-high business volume of RMB8.89 billion in the first half of 2024, representing a year-on-year increase of 10.3%. Club Med’s business in the Europe, Middle East and Africa (EMEA) region and the Americas continued to grow, and its business in Asia-Pacific region recovered significantly. In May 2024, Club Med signed an agreement in Oman for the launch of its first resort in the Middle East.Fosun Insurance Portugal, which began its operations in Portugal, has been actively expanding into overseas markets. In the first half of 2024, it achieved business growth domestically and internationally. The contribution from overseas markets further increased, with international business recording premiums of EUR885 million, accounting for over 30% of the total premiums; the net profit of international business was approximately EUR51 million, accounting for over 40%.Easun Technology, a global leading automation and digitalization company under Fosun, has also been advancing its overseas expansion. In the first half of 2024, it achieved new overseas orders of RMB3.99 billion, with a significant increase in orders from the U.S. market, reaching RMB750 million, more than doubling year-on-year.Innovation is also a core competence that Fosun has accumulated over a long period of time and has always adhered to. During the reporting period, Fosun invested a total of RMB3.5 billion to deepen its technological and innovation capabilities. Its integrated innovation model under a global vision has become more mature, resulting in a number of ground-breaking achievements that are steadily generating profits and driving Fosun’s growth.In terms of innovative drug R&D, Fosun Pharma has 4 products with a total of 9 indications were approved for marketing; 4 products with a total of 9 indications had entered the pre-launch approval stage/key clinical stage; and 9 products (by indication) have been approved to conduct clinical trials. Shanghai Henlius’ independently developed and manufactured innovative biologics continue to make breakthroughs. The world’s first anti-PD-1 monoclonal antibody for the first-line treatment of small cell lung cancer (SCLC), HANSIZHUANG, has been approved for 4 indications, benefiting over 75,000 patients. It has also been out-licensed to over 70 countries and regions, including the U.S., Europe, Southeast Asia, the Middle East, and North Africa. In addition, the new indication for SUKEXIN, a new generation of oral thrombopoietin receptor agonist (TPO-RA), has been approved by the National Medical Products Administration (NMPA).New progress has also been made in the deployment of cutting-edge medical devices and innovative therapies. In June 2024, Intuitive Fosun Headquarters Industrial Base was inaugurated in Shanghai. It is the largest integrated R&D, production and training base of Intuitive Surgical in the Asia-Pacific region, significantly accelerating the localization of the da Vinci surgical robot. Intuitive Fosun’s Ion robotic bronchoscopy was approved by the NMPA in March this year and was launched in July 2024.“Asset-light operations” taking shape, poised for revaluationBenefitting from the strong support in its business operations, Fosun’s financials have also continued to improve. During the reporting period, Fosun continuously optimized its asset portfolio, continuously reduced leverage, and maintained a sound financial position. As of 30 June 2024, the Group’s adjusted total debt-to-capital ratio was 50.2%, maintaining a downward trend since 2020. Adjusted NAV was HK$17.4 per share, indicating that Fosun International’s current share price is significantly undervalued.Meanwhile, Fosun has actively strengthened its financial cushion and maintained ample cash reserves. As of 30 June 2024, Fosun International’s cash and bank balances and term deposits reached RMB109.55 billion, representing an increase of RMB17.1 billion compared to the end of 2023. In the 17 years since its listing, Fosun has accumulatively paid out HK$25.6 billion in dividends, with the dividend payout ratio gradually increasing to over 20% in the past five years.In June 2024, the international rating agency S&P fully recognized the effectiveness of Fosun’s financial strategy and affirmed its rating outlook as “stable”.While achieving stable profits through ongoing innovation and globalization, Fosun has also responded to the new market environment by streamlining its business. It has progressively exited some non-core industries and has actively advanced its asset-light strategy, which is now taking shape.In May 2024, Fosun sold all of its 99.74% stake in the German private bank HAL, which attracted market attention. After the completion of the transaction, Fosun will no longer hold any shares in HAL, but will retain the HAFS asset servicing business, managing approximately EUR100 billion in assets in an asset-light operation model.In the tourism sector, Fosun’s asset-light operation model has achieved remarkable results, with IPs such as Club Med, Atlantis Sanya, and Taicang Alps becoming benchmarks in the domestic tourism industry. In the first half of 2024, 85% of Club Med resorts adopted a leasing and management model, with the proportion of self-owned resorts declining to 15%.In April 2024, the AMAZE Snow Mountain Camp, FTG’s new IP in Lijiang Club Med Resort, quickly became a hit after its opening, driving significant occupancy increases at the nearby Club Med Lijiang Resort and Joy Holiday Hotel Lijiang.In June 2024, FTG joined hands with the Taicang Municipal Government to build the phase II of Taicang Alps Resort, a one-stop ice and snow-themed urban tourist destination. The phase II project, with a total investment of over RMB5 billion, is funded by the Taicang Municipal Government and operated and managed by FTG. The successful operation of the Alps Snow Live has provided confidence and momentum for the phase II project, which is expected to set several world records in ski resorts.Fosun has also joined hands with partners to set up a number of industry funds to drive the future of advantageous industries. In March 2024, leveraging its leading advantages in biomedicine, Fosun Pharma joined hands with Shenzhen Guidance Fund and seven other investors to jointly establish a RMB5.0 billion biomedical industry fund, with all proceeds to be invested in biomedical, cells, genes, etc. Shanghai Fujian Equity Investment Fund Management, a subsidiary of Fosun Pharma, was selected through public selection process in Shenzhen to exclusively manage this fund. In April this year, the Shenzhen Municipal Government and Fosun signed a strategic cooperation framework agreement, both parties will further strengthen cooperation in areas such as biomedicine, cultural and sports tourism, and fashionable consumption.In addition, Fosun Capital, together with Wuhan Innovation Investment and Wuhan Fund, established a RMB3.0 billion industry fund with an initial scale of RMB1.1 billion in April 2024. This is the first batch of market-oriented fund invested by Hubei Province since the establishment of the RMB20.0 billion government guidance fund, mainly focusing on the four major sectors of new generation information technology, dual carbon, intelligent manufacturing, and consumption.Given the current market environment, it is expected that Fosun will continue to focus on asset-light operations, continuously expand its “circle of friends”, strengthen in-depth cooperation with all parties, and achieve win-win results through complementing each other’s advantages.Market analysts believe that Fosun has achieved sustained and stable profits leveraging its core strategies of innovation and globalization. In addition, by exiting non-core assets, pursuing asset-light operations, and continuously reducing debt, Fosun has maintained robust financial health, paving the way for a potential market revaluation.Guo Guangchang believes that in the future, investors will place greater emphasis on the growth of core industries and the stability of cash flow. “One-off asset sales are only short-term solutions. The growth of core businesses is crucial for a company to achieve stable profits.” Fosun aims to build a consumer group centered on core industries, ensuring more predictable business development and profits. At both the group level and within each business unit, Fosun is committed to creating value for its customers and investors that is manageable in terms of risk and promotes steady growth. Copyright 2024 ACN Newswire via SeaPRwire.com.

2024年上半年財務摘要- 合併實現收入人民幣18,339,730千元，比上年同期增長22.01%，高於行業增長水平；- 歸屬於公司所有者的期間利潤人民幣3,498,318千元，比上年同期增長23.36%；- 每股收益人民幣1.34元，比上年同期增長22.94%。香港, 2024年8月29日 - (亞太商訊 via SeaPRwire.com) — 福耀玻璃工業集團股份有限公司（「福耀玻璃」或「公司」；股份代號：600660.SH、3606.HK）欣然宣佈公司及其附屬公司截至2024年6月30日止六個月（「報告期」）的未經審計中期業績。緊抓市場機遇  營收利潤雙雙強勁增長2024年上半年，全球經濟增速緩慢復甦，國際局勢複雜多變，地緣政治衝突加劇，全球產業鏈和供應鏈穩定性仍受到挑戰。中國汽車行業伴隨以舊換新、地方配套政策出台等，主要經濟指標呈增長態勢，根據中國汽車工業協會統計，2024年1-6月，汽車產銷分別為1,389.1萬輛和1,404.7萬輛，同比分別增長4.9%和6.1%。公司積極把握市場機遇，以技術創新引領製造升級，同時通過數字化升級提升效率，高質量發展穩步推進，盈利能力進一步提升。報告期內，公司合併實現收入人民幣18,339,730千元，比上年同期增長22.01%，高於行業增長水平；實現除稅前利潤人民幣4,125,070千元，比上年同期增長24.27%，實現歸屬於公司所有者的期間利潤人民幣3,498,318千元，比上年同期增長23.36%；實現每股收益人民幣1.34元，比上年同期增長22.94%。報告期內，公司除稅前利潤比上年同期增長24.27%。若扣除匯兌損失以及太原金諾實業有限公司終止履行福耀集團北京福通安全玻璃有限公司剩餘24%股權轉讓的相關約定導致投資收益減少影響，報告期除稅前利潤比上年同期增長59.96%。全面提升綜合競爭力  高附加值產品表現亮眼報告期內，公司圍繞集團經營戰略，以「為客戶持續創造價值」為中心，以市場為導向，以技術創新為支持，以規範管理為保障，全面提升公司綜合競爭力。在產品質量方面，公司從產品設計、原料採購、生產製造到成品進倉每個環節均進行嚴格的質量把控，提升全過程質量管控能力，確保產品的質量和可靠性，有效預防和控制質量問題的發生。在供應方面，公司不斷提高全球保供能力，根據行業趨勢提前規劃佈局，構建完整的全球供應體系；同時對生產過程進行持續創新和優化，縮短產品從投料到進倉的時間，構建柔性敏捷生產能力，保證全球化的交付和能力，與汽車行業相互成就，共同成長。在創新能力建設方面，公司在技術、管理等各領域持續加大創新力度，智能全景天幕玻璃、可調光玻璃、抬頭顯示玻璃、超隔絕玻璃、輕量化超薄玻璃、鍍膜可加熱玻璃、鋼化夾層玻璃等高附加值產品佔比持續提升，佔比較上年同期上升4.82個百分點，價值得以體現。在銷售方面，公司始終把客戶需求放在第一位，堅持快速反應，高效服務，與客戶建立高度的信任關係，持續以為客戶創造價值為核心，構建福耀銷售組織形式，提升銷售管理能力，加大市場拓展力度，拓寬銷售渠道，提升銷售質效。在團隊建設方面，公司堅持以人為本，保障具有競爭力的員工福利待遇，推動福耀的人文建設，樹立良好的紀律和工作作風，構建一支更加積極、高效的國際化團隊。公司表示：「2024年下半年，全球經濟形勢依然嚴峻，經濟增長仍面臨多重風險挑戰。為此，福耀玻璃將穩健經營、謹慎走好每一步：嚴控產品質量和新產品開發的各個環節，細化工作，用好「質量一票否決制」，進一步營造良好質量文化，形成人人關心質量，人人重視質量的工作氛圍；業務規模擴大的同時，持續優化生產過程，建立敏捷管理、柔性生產機制，保證全球化的交付和服務，確保公司高質量發展；圍繞新材料、新工藝、新技術、跨領域合作等方面，持續加強技術創新，加大研發投入，加快研發速度，推動產品的升級換代，提升福耀的核心競爭力；加強數字化建設，將作業數字化，數字平台化，平台智能化，智能實戰化，實際經營過程各領域數據透明、共享、易懂、有用，發揮數字化的效率；繼續發揮銷售引領作用，建立全方位銷售管理機制，多市場發力，國內外並舉，拓展新客戶、穩定老客戶，優化服務水平，提高客戶滿意度，增強企業競爭力；持續加大人才培養力度，培養新技術、管理、自動化、數字化、國際化等領域的專業人才，落實員工發展，提升組織效能，提升企業形象和品牌價值。」                                             - 完 -有關福耀玻璃工業集團股份有限公司福耀集團（全稱福耀玻璃工業集團股份有限公司），1987年成立于中國福州，是專注於汽車安全玻璃的大型跨國集團，於1993年在上海證券交易所主板上市（A股代碼：600660），於2015年在香港交易所上市（H股代碼：3606），形成兼跨境內外兩大資本平台的「A+H」模式。公司的主營業務是為各種交通運輸工具提供安全玻璃和汽車飾件全解決方案，包括汽車級浮法玻璃、汽車玻璃、機車玻璃、行李架、車窗飾件相關的設計、生產、銷售及服務，公司的經營模式為全球化研發、設計、製造、配送及售後服務，奉行技術領先和快速反應的品牌發展戰略，與客戶一道同步設計、製造、服務、專注於產業生態鏈的完善，系統地、專業地、快速地響應客戶日新月異的需求，為客戶創造價值。 Copyright 2024 亞太商訊 via SeaPRwire.com.

香港, 2024年8月30日 - (亞太商訊 via SeaPRwire.com) — 近日，中國光大環境（集團）有限公司（257.HK）（下稱“光大環境”或“公司”）公布了2024中期業績。作爲一站式、全方位的環境綜合治理服務商，光大環境不僅保持業務穩健增長，更在環境保護和社會責任方面發揮重要作用，引領行業標杆。綠色科創賦能未來 廣泛推動綠色合作光大環境積極參與高層行業對話和國際論壇，推動區域環境合作。2024年上半年，公司管理層先後出席了美麗中國百人論壇2024年會、上海合作組織國家綠色發展論壇。在上海合作組織國家綠色發展論壇上，光大環境與各國代表共同探討綠色發展戰略，爲全球綠色發展貢獻中國方案。論壇期間，光大環境總裁欒祖盛參與了“産業集聚共建繁榮上合”主題環節，幷以《發展綠色生産力 共建可持續未來》爲題發言，重點分享了開展務實科技交流，構建綠色創新生態圈；推動低碳産能合作，打造綠色産業聚集區；加快標志項目落地，樹立綠色上合新標杆三方面的思考。此外，公司作爲參建單位受邀還出席了海南博鰲近零碳示範區運行啓動會。今年上半年，公司旗下越南順化垃圾發電項目竣工儀式獲越南國家政府總理出席，同時，公司亦受邀出席越南總理與在越中資企業的座談會，展示了中國企業在“一帶一路”倡議下的擔當和影響力。公開透明溝通 提升市場形象秉持開放透明的原則，光大環境主動接受各界監督，展現了高度的企業責任感和治理水平。2024年上半年，公司組織了近20次項目考察活動，吸引逾百家境內外投資機構參加。這些考察活動涵蓋了公司在垃圾發電、水環境治理、生物質能利用等多個領域的代表性項目，讓投資者、分析師和媒體代表深入瞭解了光大環境的運營模式、技術創新和發展戰略。通過面對面交流和實地考察，公司深化了與各利益相關方的溝通，增進了相互理解和信任。這種開放、透明的溝通策略不僅提升了公司的市場形象，也爲吸引更多投資者和合作夥伴奠定了堅實基礎。截至2024年6月30日，已有23家機構給予光大環境正面評級，公司股價較2023年底升逾50%。倡導環保低碳 携手各界築綠光大環境積極推動環保宣傳，致力于提升公衆的環保意識和參與度。在內地，公司圍繞“世界水日”、“世界環境日”等重要環保主題日，在全國各地的項目公司組織開展了形式多樣、內容豐富的環保活動。在日常亦通過策劃幷組織主題形式多樣的公益活動，深入當地社區，與民衆互利共融，吸引了大量市民參與，有效普及了環保知識，培養了公衆的環保習慣。截至2024年6月30日，光大環境累計有220個項目向公衆開放，綫下接待境內外各界參觀考察人士約9,500人次，參與和觀看綫上活動的人數約8萬人次。獲頒多項榮譽，鞏固行業影響力2024年上半年，光大環境憑藉卓越的經營業績和社會貢獻，收穫多項榮譽。公司連續13年位居中國“年度固廢十大影響力企業”榜首，獲標普第七次納入《可持續發展年鑒》；旗下光大水務連續7年入選“中國水業十大影響力企業”榜單；光大綠色環保更是第3次獲評《亞洲周刊》全球卓越ESG大獎。這些榮譽和成就進一步鞏固了光大環境在環保領域的領軍地位，爲公司未來的發展注入了强勁動力。面對國家“雙碳”目標和對照中國式現代化建設目標要求，作爲行業領軍企業，光大環境在推動綠色低碳發展、改善生態環境質量、促進經濟社會可持續發展等方面發揮了重要作用。公司管理層表示，未來，光大環境將繼續秉持“創造更好投資價值，承擔更多社會責任”的企業使命，堅持創新驅動，深化國際合作，不斷提升環境治理能力和水平，爲中國生態文明建設和全球可持續發展貢獻更大力量。 Copyright 2024 亞太商訊 via SeaPRwire.com.

香港, 2024年8月30日 - (亞太商訊 via SeaPRwire.com) — 在數字化浪潮的推動下，遊戲行業正經歷著前所未有的變革。中手游（0302.HK）作為全球化IP遊戲運營商的領軍企業，憑藉其在遊戲發行及研發領域的深厚積累，正以創新的姿態，推動著行業的穩步發展，引領著遊戲行業的新潮流。8月28日，中手游發佈2024年中期業績。數據顯示，上半年公司實現收益約為人民幣12.33億元，毛利約為人民幣3.73億元，毛利率為30.2%。其中，海外業務收入人民幣1.76億元，同比增長41.5%，顯示出公司在國際市場的強勁競爭力，進一步鞏固了其在文娛產業中的領先地位。產品質量優秀獲市場青睞 海外業務表現突出中手游是中國知名的移動遊戲開發商和發行商，專注于提供高品質的遊戲內容和卓越的用戶體驗。公司主營業務主要涵蓋IP遊戲的全球發行、遊戲自主研發以及自有IP運營三大板塊，三大板塊相互協同，構成多元化業務佈局。在IP遊戲全球發行方面，中手游依託其豐富的知識產權資源，專注于打造具有深厚文化底蘊的IP遊戲精品。2024年初，中手游與貪玩遊戲聯合發行的《鬥羅大陸：史萊克學院》正式上線，上線前預約玩家數超過600萬人，上線首月便在蘋果商店免費榜和TapTap熱門榜上斬獲第一名，被華為開發者大會評為年度最佳國漫IP遊戲，首月流水突破1億元人民幣，充分展現了該IP的巨大人氣和玩家的消費潛力。繼《鬥羅大陸：史萊克學院》之後，中手游投資的深圳易帆互動科技有限公司研發的《鬥破蒼穹：巔峰對決》也於2024年6月在中國大陸地區上線，上線前預約量突破600萬，上線首月便在蘋果商店免費榜上獲得第二名，成為硬核聯盟超明星推薦的遊戲。同時，中手游在小遊戲領域的佈局也取得了顯著成效。2024年上半年推出的《消個錘子》上線後迅速沖上微信遊戲暢銷榜第32位，並在小遊戲塔防三合消除品類遊戲中名列第一，另一款小遊戲《主公別跑》也錄得連續多月月流水過千萬的優異成績。海外市場方面，基於自有IP《仙劍奇俠傳》打造的《新仙劍奇俠傳之揮劍問情》在港澳台地區上線後，首月便在蘋果應用商店免費榜和暢銷榜上取得優異成績。截至2024年6月30日，海外業務收入佔公司收益的比重達到14.3%。通過精心研發和市場洞察，中手游不僅成功打造了一系列備受矚目的手遊作品，在國內市場取得了顯著的成績，更在國際舞台上展現了中國遊戲產業的競爭力，一系列令人矚目的成就，彰顯卓越的研發創新實力與行業領導地位。自主研發項目穩步推進 有望引領行業發展遊戲自主研發是中手游構建核心競爭力的關鍵。公司旗下的滿天星工作室自主研發的《仙劍世界》經過三年的精心打磨，已獲得PC端和移動端雙端版號。這款遊戲以其獨特的國風美學和豐富的遊戲內容，吸引了近500萬玩家的預約，多次被評為年度「最受期待遊戲」，該項目即將迎來第四次終測，並計劃於2024年內正式上線，展現了中手游在自主研發領域的強大生命力和競爭力。中手游全資子公司——文脈互動自主研發的三國題材戰略遊戲《城主天下》，雖然目前仍處於上線後的調優階段，但《城主天下》已經展現出其獨特的魅力和潛力。預計在2024年下半年完成調優後，將全面擴大推廣規模，為玩家帶來更深入的策略遊戲體驗。繼《傳奇世界之雷霆霸業》取得單月最高月流水超過人民幣2億元的佳績後，文脈互動再接再厲，推出了另一款自主研發的傳奇品類遊戲《代號：暗夜傳奇》。這款遊戲目前已經完成研發，即將開始上線前測試，並計劃於2024年正式上線。截至2024年6月30日止六個月，公司錄得遊戲開發收入人民幣126.3百萬元。以匠心獨運的自主研發實力，中手游不斷為玩家帶來高品質的遊戲體驗。可以預期，隨著項目的不斷上線運營，未來將為公司帶來更廣闊的成長空間和增長潛力，公司亦將在遊戲行業的藍海中乘風破浪，持續引領行業發展。自有IP運營持續深化合作 構築堅固護城河自有IP運營方面，2024年初，中手游與愛奇藝等合作夥伴攜手，將《仙劍奇俠傳四》改編為同名影視劇，在愛奇藝平台播出，為觀眾帶來了一場視覺與情感的盛宴。同時，基於《仙劍奇俠傳六》改編的《祁今朝》也在騰訊視頻平台播出，進一步擴大了仙劍系列的影響力。4月，與企鵝影視合作的《又見逍遙》上映，贏得了觀眾的廣泛好評。同時，中手游在互動影像領域邁出了創新步伐。2023年11月，公司聯合東陽奇樹有魚文化傳媒有限公司等合作夥伴，正式啟動了基於《仙劍奇俠傳》IP的互動影像作品製作，旨在為觀眾提供更加沉浸式的體驗。此外，在動漫領域，中手游與企鵝影視達成戰略合作，共同製作《仙劍奇俠傳一》及《仙劍奇俠傳三》的動畫番劇。《仙劍奇俠傳三》動畫預告片已於2023年推出，正片計劃於2025年上映。此外，與嗶哩嗶哩合作的《仙劍奇俠傳四》動畫番劇也在立項製作中，為仙劍迷們帶來了新的期待。值得一提的是，2024年上半年，中手游與超競集團達成戰略合作，利用旗下EDG電子競技俱樂部和MCN機構達人資源，以及關聯企業合生商業有限公司的商業綜合體等線下業態，為IP遊戲發行帶來了新的流量和玩家增量，發揮仙劍IP的影響力和挖掘IP商業價值，進而為公司長期發展構築堅固護城河。總體而言，以IP為核心，中手游通過不斷的創新和研發，不僅在遊戲行業樹立了新的標杆，更為中華文化的傳播貢獻了力量。隨著公司在自主研發和IP運營方面的不斷深化，我們有理由相信，中手游將繼續引領遊戲行業的創新發展，為全球玩家帶來更多精品遊戲，為股東和投資者帶來長期回報。 Copyright 2024 亞太商訊 via SeaPRwire.com.

香港, 2024年8月30日 - (亞太商訊 via SeaPRwire.com) — 渤海銀行股份有限公司（「渤海銀行」或「公司」；股份代號：9668.HK）宣佈公司及其附屬公司（「集團」）截至2024年6月30日止六個月（「報告期」）之未經審計綜合中期業績。2024年上半年，國際環境更趨複雜嚴峻，主要經濟體經濟增長與貨幣政策有所分化。中國經濟運行延續回升向好態勢，高質量發展扎實推進，但仍面臨有效需求不足、企業經營壓力較大、重點領域風險隱患較多等困難。集團全面落實監管政策要求，堅持穩中求進工作總基調，以進促穩，先立後破，持續推進「十個專項工作」攻堅，扎實落地高質量發展方案各項目標任務，優化業務布局，狠抓科技創新，突出轉型驅動，強化風險防控，在轉方式、調結構、提質量、增效益上積極進取，推動高質量發展取得新成效。報告期內，集團實現營業收入131.45億元，淨利潤36.97億元，總體保持了平穩發展態勢。截至報告期末，資產總額17,479.96億元，較上年末新增152.62億元，增幅0.88%。其中，發放貸款和墊款總額（未含應計利息）為9,478.52億元，較上年末新增152.08億元，增幅1.63%；負債總額16,294.25億元，較上年末新增110.94億元，增幅0.69%。其中，吸收存款總額（未含應計利息）9,346.22億元，較上年末新增194.60億元，增幅2.13%；不良貸款餘額為171.12億元，比上年末增加5.54億元；不良貸款率為1.81%，比上年末上升0.03個百分點。貸款損失準備計提充足，貸款減值準備271.07億元，比上年末增加11.20億元。貸款撥備率2.86%，撥備覆蓋率158.41%，均符合監管要求。回歸服務實體經濟本源  扎實推進公司銀行業務高質量轉型報告期內，公司銀行以服務國家戰略目標和實體經濟為根本宗旨，緊緊圍繞做好科技金融、綠色金融、普惠金融、養老金融、數字金融五篇大文章，堅持行業銀行、交易銀行、輕型銀行定位，優化業務結構，提升經營水平，扎實推進公司銀行業務高質量轉型發展。客戶建設方面，報告期內，公司銀行堅持以客戶為中心，持續完善行業戰略客群、基礎專項客群、政府機構客群、區域重點客群等四大對公客群服務體系。截至報告期末，公司銀行全量客戶合計111,472戶，比上年末增加6,040戶，增長5.73%。負債業務方面，公司銀行始終堅持「存款為本」的理念，通過傳統及非傳統信貸產品組合應用，搭建業務場景，為客戶提供綜合金融服務，積極拓展低成本存款。同時，推進數字化系統建設，完善產品功能，提升服務水平，優化客戶體驗，推動存款規模增長和存款結構優化。截至報告期末，公司存款總額5,942.76億元，比上年末增加281.09億元，增長4.96%。資產業務方面，公司銀行圍繞服務實體經濟，持續加大對科技金融、製造業、綠色信貸、鄉村振興等重點領域的支持力度。製造業、科創類小微企業、綠色金融、涉農等重點領域貸款增速均大幅高於一般性貸款增速。截至報告期末，公司貸款總額6,366.66億元，比上年末增加699.26億元，增長12.34%。科技企業貸款餘額438.95億元，其中專精特新企業貸款餘額同比增長23.03%，高技術產業貸款餘額同比增長22.08%，知識產權密集型產業貸款餘額同比增長12.79%；製造業貸款餘額912.79億元，較上年末增長6.84%；綠色貸款餘額377.45億元，較上年末增長20.75%；涉農貸款餘額419.16億元，較上年末增長15.62%。交易銀行業務方面，交易銀行持續加強產品化、場景化、線上化建設，圍繞供應鏈金融、票據服務、現金管理解決方案、國際結算與貿易融資，構築交易銀行業務生態，深挖客戶需求，為客戶提供一站式服務體驗。報告期內，交易銀行實現非息收入9.60億元，同比增長5.73%。其中，價差收入1.43億元，同比增長268.98%。交易銀行業務表內外資產規模4,707.4億元， 同比增長14.17%；累計投放4,347.77億元，同比增長78.23%。全行線上公司業務客戶數13,286戶，新一代票據業務活躍客戶數2,109戶。實現國內信用證及福費廷業務投放1,163.61億元。海納池累計投放金額124.19億元，在池資產規模156.54億元。投資銀行業務方面，集團堅定FPA經營發展轉型方向，着力打造流量銀行，盤活存量、用好增量、做大流量，以具有比較優勢的鈎子產品作為業務破局點，將服務經濟融資總量作為工作的出發點和落腳點，持續優化業務結構、豐富收入來源、發力渠道拓展、夯實客戶基礎，強化通過債券承銷、交易撮合、資產流轉、理財子公司對接等高效利用資本方式實現拓展客戶、沉澱存款、提升效益的能力。2024年上半年，投資銀行債券主承銷業務規模913.56億元，同比增長105.48%；累計承銷各類創新債券（含結構化融資產品）31隻，承銷金額合計120.17億元。交易撮合業務穩步發展，報告期內，撮合對接資產規模433.25億元，同比增長5.78%。資產託管業務方面，報告期內，資產託管業務扎實履行服務實體經濟高質量發展職能，堅持專業化、規範化發展，持續優化運營流程，夯實客戶基礎，探索創新服務模式，推動託管規模快速提升。截至報告期末，資產託管及外包業務規模餘額28,058.55億元；報告期內，實現資產託管及外包業務收入15,417.77萬元。根據中國銀行業協會2024年第二季度統計數據，集團託管規模排名第20位。普惠金融業務方面，報告期內，集團重點聚焦普惠金融產品譜系打造，着力構建「鏈系列、數系列、快系列、科系列」四大普惠金融產品譜系，實現線上線下相結合，大幅提升服務效率和客戶體驗，打造具有渤海特色的普惠服務品牌。截至報告期末，集團普惠貸款餘額457.35億元；普惠貸款客戶數87,402戶；當年累放貸款執行利率4.4%。着力打造賬戶銀行、財富銀行、生態銀行  零售銀行業務穩步發展報告期內，零售銀行着力打造賬戶銀行、財富銀行、生態銀行，推進「賬戶+支付+金融產品」的綜合服務體系建設，強化生態拓客模式，依託技術支撐和數字驅動，深化客戶分層分群經營，以客戶視角聚合產品服務，優化產品譜系，改善業務結構，推進零售業務穩步發展。截至報告期末，集團零售存款餘額2,103.19億元，較上年末增加93.17億元。客戶發展方面，集團加快數字化運營能力突破，聚焦多元渠道建設、拓客模式轉型和生態場景搭建，完善客戶分層分群經營服務策略，優化代發和支付服務工具，促進零售客戶增量提質。截至報告期末，集團零售客戶總量793.18萬戶，較年初淨增21.93萬戶。資產業務方面，報告期內，零售資產業務以國家信貸政策為導向，加快推進業務高質量轉型發展，堅持以客戶為中心，滿足客戶多樣化信貸需求。截至報告期末，個人貸款餘額2,247.65億元。財富管理方面，持續打造「渤銀E財」產品貨架，提升產品供應能力。報告期內，零售財富資產規模穩步提升，同比增長407.24%，其中代銷理財存量規模增速較上年同期提升26.25個百分點，代銷信託存量規模同比增長116.14%，發展勢頭良好。私人銀行專業化服務成效日益凸顯，截至報告期末，私人銀行投資理財類產品的覆蓋度較年初提升1.23個百分點。信用卡業務方面，集團聚焦金領貸客群、房貸客群，將信用卡打造成為增強零售優質客群黏性的有效載體。截至報告期末，信用卡累計發卡量126.42萬張，貸款規模41.89億元。提升金融市場業務創新轉型發展能力  樹立行業口碑報告期內，集團金融市場業務堅決踐行轉型振興高質量發展要求，以建設市場領先的金融市場FICC業務中心為目標，牢牢守住風險底線，深耕同業客戶基礎，強化銷售交易能力建設，確保全行流動性安全，金融科技賦能業務發展，堅持金融服務實體經濟，各項工作取得顯著成果。理財業務方面，集團持續豐富理財產品種類，優化產品功能，為客戶提供更好的理財服務。同時積極拓展行外代銷渠道，拓寬資產管理服務客群，已與26家機構達成代銷合作。報告期內，集團共發行理財產品204隻，銷售金額合計2,048.85億元。截至報告期末，集團存續理財產品358隻，理財產品餘額1,677.01億元，淨值型產品佔比91.72%。資金業務方面，密切關注市場走勢，加強市場研判，積極開展各類貨幣市場交易業務，上半年開展人民幣債券質押式回購交易約5.57萬億元，同比增長5.96%，獲得中國人民銀行2024年度公開市場業務一級交易商資質，並獲評中國外匯交易中心回購活躍交易商，大幅提高銀行間市場影響力。同時，緊抓市場機遇，踴躍參與外匯交易中心各類標準化交易業務，外匯交易各項排名較上年同期均有不同程度的提升，其中人民幣外匯掉期交易排名躋身銀行間市場45強。債券業務方面，持續加強債券業務模式和產品創新，做大債券投資交易規模，債券市場影響力、貨幣政策傳導能力、雙邊做市服務能力有效提升。報告期內，各類金融市場債券業務量保持穩步增長，現券交易量2.9萬億元，同比增長70%。同業業務方面，集團持續探索並推進同業客戶一體化經營。繼續完善同業產品貨架，以銷售促轉型穩步推進，客戶綜合貢獻穩步提升，同業朋友圈更加豐富完備。報告期內，實現屬地目標同業客戶覆蓋率43.4%，多元產品滲透率34.81%。同業授信方面，報告期內，境內外同業機構對集團授信額度充足、品種廣泛，滿足全行各項業務穩定發展需要。截至報告期末，集團累計獲得超過1,300家同業機構授信，授信總額1.6萬億元人民幣。聚焦數字金融和智慧金融  持續推進網絡金融業務報告期內，集團網絡金融業務聚焦數字金融和智慧金融，持續推進線上用戶運營和門戶渠道建設，通過技術與數據賦能，加速實現綜合化服務升級和經營轉型發展。手機銀行方面，集團重點圍繞賬戶銀行、財富銀行和生態銀行戰略定位，逐步從功能建設向客戶經營轉型並成功升級至6.3版，通過建立事件型營銷體系和數字化全域經營促進移動端月活客戶數量和財富產品成交量持續提升。門戶網站方面，集團於2024年5月完成門戶網站系統重構，實現全面升級，為客戶提供智能化服務新體驗。在生態化經營方面，集團持續深耕教育服務場景，深化場景化服務新模式，打造全方位服務客戶的生態體系。展望未來2024年下半年，集團將全面落實監管政策要求，遵金融規律、守金融向善、求金融真實，以改革精神做強主責主業，更加注重統籌聯動，更加注重突出重點，更加注重實績實效，持續集中全力轉方式、調結構、提質量、增效益，努力開創高質量發展新局面。 Copyright 2024 亞太商訊 via SeaPRwire.com.

- Dorzagliatin (trade name: HuaTangNing, world's first dual-acting glucokinase activator (GKA), successfully entered China’s National Reimbursement Drug List for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (the “NRDL”) at the end of 2023. Hua Medicine worked with sales promotion partner Bayer Healthcare Company Limited (“Bayer”) and 80 Tier 1 distributors to begin the pharmaceutical market entry in 31 municipalities and provinces in China.- The new NRDL became effective on January 1, 2024. In the first half of 2024, the sales volume of dorzagliatin increased significantly. As of June 30, 2024, sales of HuaTangNing  reached 846,000 packs with a sales revenue of RMB102.7 million. The sales revenue increased by 46%, compared with the six months ended June 30, 2023.- Dorzagliatin experienced a fast entry into hospitals, especially in Shanghai, Beijing, Tianjin where the government policies support market entry for novel new drugs. By the end of June 30, 2024, dorzagliatin was prescribed in over 2,100 hospitals and over 2,900 pharmacies. Dorzagliatin was sold principally through hospitals (approximately 72% of total sales), with the remainder of sales through pharmacies (20%) and internet drug stores (8%).- Gross profit in the first half of 2024 is RMB47.8 million, representing a gross profit margin of 46.5%. Bank balances and cash position increased by 51.9% to approximately RMB1,338.8 million for the six months ended June 30, 2024, compared with the six months ended June 30, 2023.- Dorzagliatin manufacturing capacity continues to expand, with the expectation to reach 3 million packs in 2024. New processes for larger capacity have been established with our partners and are under regulatory review for production permit.- Post marketing clinical studies proceeded at an accelerated rate, in which HMM0601 enrolled 1,368 patients and HMM0701 enrolled 102 patients. HMM0601 is designed to evaluate the long-term safety of dorzagliatin by collecting 1-year clinical safety data in 2,000 T2D patients and HMM0701 is a prospective real-world study to explore dorzagliatin’s clinical beneficial effects on the improvement of glucose homeostasis, cognitive function and diabetes remission. A good drug safety profile for dorzagliatin has been observed since its commercial launch in October 2022 – a time span of over 20 months and approximately 100,000 patient exposure.- Two Mendelian randomization studies conducted by our collaborating Hong Kong-based clinical investigators, and published in Cardiovascular Diabetology showed that glucokinase activation can lead to long term benefits in reduction of risks in cardiovascular diseases and dyslipidaemia. New clinical indications shall be further explored with our commercialization partner.HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) -  Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company’s business progress for the first half of the year and business outlook.Dr. Li Chen, the founder and CEO of Hua Medicine, said, “The first half of 2024 marks a milestone for the commercialization efforts of Hua Medicine. Dorzagliatin's successful inclusion in China’s National Reimbursement Drug List has significantly improved patient accessibility and affordability. Against the backdrop of comprehensive support from the national and local governments for the development of the biopharmaceutical industry, and with the joint efforts of the Company, commercial partners, and production partners, the production capacity of dorzagliatin is rapidly increasing, accelerating its entry into hospitals and pharmacies nationwide to benefit more patients. With the continued growth in the number of users, the safety of dorzagliatin has been well validated, and its economic and social benefits have also greatly increased, instilling confidence in the Company's future development. Through sales expansion and operational optimization, we hope to achieve profitability for the Company by 2025. Currently, Hua Medicine is also conducting basic and clinical research on dorzagliatin globally, aiming to continuously expand its indications and target populations, explore new disease areas, and promote human health and well-being.”Progress of Clinical Research and Company Operations- During the first reporting period under the NRDL, dorzagliatin experienced a fast entry into hospital and pharmacies, especially in Shanghai, Beijing, Tianjin where the government policies support market entry for novel new drugs. The number of hospitals prescribing dorzagliatin exceeded 2,100 in the first half of 2024.- Revenue of dorzagliatin reached RMB102.7 million in the first half of 2024 and is expected to continue to grow in the second half of 2024. As we build off our new foundation under the NRDL, we plan to leverage our well-established partnerships to enhance the dorzagliatin manufacturing process, which is expected to lead to efficiencies, expanded capacity and reduction of cost of goods.- We continued our post marketing clinical studies at approximately 80 hospitals to better understand the benefits dorzagliatin provides to patients with Type 2 diabetes and T2D complications, such as memory loss and diabetes kidney disease. Through our collaboration with our clinical research partners in Hong Kong, we have discovered that glucokinase (GK) activation may bring the benefits of reduction of risks in cardiovascular disease, and dyslipidemia. These results (applying the Mendelian Randomization (MR) methodology) certainly expand our understanding of the benefits of GK activation through dorzagliatin and for uncovering new indications of dorzagliatin in the future. Mendelian Randomization (MR) is a statistical method that uses genetic variants to investigate the causal effects of exposures (e.g., treatments) on outcomes (e.g., diseases). Its unique advantage lies in its reduced susceptibility to confounding and time-related biases compared with observational studies, which is achieved by leveraging the random allocation of genetic variants at conception. In evidence-based medicine, the credibility of evidence from MR is considered to be among the highest, second only to that of randomized controlled trials.- We have advanced our post-marketing real world evidence (RWE) studies HMM0601 and HMM0701 in T2D patients in China, and HMM0123 in Hong Kong, China. In these studies, we are collecting evidence in medical practices for optimization of glucose homeostasis either through dorzagliatin alone or in combination with standard care T2D medications such as metformin, DPP-IV inhibitors, SGLT-2 inhibitors, GLP-1RA and insulin. These results create new evidence for dorzagliatin in the expansion of its indication in diabetes prevention and remission.- We are continuing our drug development pipeline with focus on the fixed dose combination (FDC) of new drug candidates. The new drug Dorzagliatin-Metformin FDC entered manufacturing process validation and our plan is to launch this new medicine for Type 2 diabetes in 2028. Additional new FDC drugs with dorzagliatin will be developed for T2D patients, tailored specifically to address T2D patients with associated complications such as obesity and diabetes kidney disease.- To further leverage the unique advantage of dorzagliatin in restoring GLP-1 secretion in patients with diabetes and obesity, Hua Medicine initiated its Phase I study in the United States with our 2nd generation GKA. The trial has been proceeding smoothly and has already completed dose escalation in three cohorts of T2D patients in the United States. The topline data is expected to be available in the fourth quarter of 2024, supporting future drug development.- At the American Diabetes Association (ADA) Annual Meeting 2024, Hua Medicine reported new scientific data supporting the combination of dorzagliatin with a SGLT-2 inhibitor which led to improvement in glycaemic control. Combination of dorzagliatin with chronic kidney disease (CKD) medicine, such as SGLT-2 inhibitor, empagliflozin, in mid to late stage diabetes kidney disease patients, offers new opportunity to expand dorzagliatin’s indication.- We are exploring more drug repurposing opportunities for dorzagliatin using MR framework, such as renal diseases, neuropathy related diseases, eye related diseases, cognitive disorders, and cancers. Animal studies shall be further performed to validate the promising findings.- We are continuing to optimize our protein allosteric modulation technology (PAMT) and expansion from positive allosteric modulator (PAM), such as GK positive allosteric modulator dorzagliatin, to negative allosteric modulator (NAM) in kinase and G-protein-coupled receptors (GPCR) proteins. The GK NAM program advanced to the pre-clinical candidate (PCC) selection stage and final optimization of the PCC to clinical candidate for congenital hyperinsulinism (CHI), and potentially for dyslipidaemia. We continue to advance mGLUR5 NAM program for its clinical potential in Parkinson’s disease (PDLID), Fragile X syndrome (FXS), and drug addiction.Financial highlightsAs of June 30, 2024,- Bank balances and cash position was approximately RMB1,338.8 million.- Total revenue generated by the Company was approximately RMB102.7 million, reflecting sales of approximately 846,000 packs of HuaTangNing .- Total other income was approximately RMB55.1 million, of which approximately RMB47.8 million was attributable to the amortization of Bayer milestone income.- Total expenditures was approximately RMB245.9 million, of which approximately RMB119.8 million was attributable to research and development expenses.Forward-looking StatementThis article contains the statements regarding the future expectations, plans and prospects for Hua Medicine and the investigational product. The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect as a result of various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin on hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with varying degrees of renal function impairment (including end-stage renal impairment without dialysis). Hua Medicine partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing  in China, benefiting diabetic patients and their families.For more informationHua MedicineWebsite:  www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.comDisclaimerFor the accuracy and completeness of the context, references to information related to products launched in China, especially label or requirements, should follow the relevant documents approved by the Chinese regulatory authorities.The above information should not be interpreted as a recommendation or promotion of any drug or treatment regimen, nor should it substitute for the medical advice of any healthcare professional. Please consult a healthcare professional for any matters related to medical treatment. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年8月30日 - (亞太商訊 via SeaPRwire.com) — 2024年，資産荒已成共識，投資者夢寐以求尋找不怕火煉的“真金”。受此影響，具有業績高確定性和高股息的資産價值凸顯。銀河證券策略首席分析師楊超指出，當前，投資者對于現金回報的重視程度日益提升，促使上市公司更積極地采取措施，主動提升分紅頻次與分紅力度。Choice數據顯示，截至8月29日，已有超百家港股上市公司披露中期分紅計劃，包括中國移動（0941.HK）、中國聯通（0762.HK）、九龍倉置業（1997.HK）、中教控股（0839.HK）、李寧（2331.HK）、朝雲集團（6601.HK）等各領域頭部公司。不過，持續高額分紅幷非易事。當前有中期分紅計劃的公司中，“中字頭”港股公司的實力不言而喻，而其他公布派息計劃公司也有一個共同特點，就是‌構建了有强大核心競爭力的行業優勢。比如九龍倉置業兩個重要商場保持穩定，業績就能穿越地産周期；比如李寧在跑步、籃球和健身三大核心專業品類上保持了科技創新；朝雲集團則以技術創新功效性産品，以履帶式爆品矩陣保持高質量可持續穩利潤發展。由此可見，能長期保持高比例派息的公司，全因其具備同業不可複製的優勢，下面就以朝雲集團為例詳作分析。一、爆品矩陣做“壓艙石”上市公司能够實施持續的高額派息，同行業內保持强競爭力，擁有良好財務狀况和盈利能力的體現。朝雲集團已連續3個半年度業績期營收純利均有雙位數的增長。8月26日發布的財報顯示，2024年H1，公司營收12.49億元（人民幣，下同），同比增長10.3%；純利1.76億元，同比增長29.6%；公司資金儲備充裕，現金、現金等價物及各項銀行存款總額為人民幣26.65億元，中期保持40%的高額派息。“履帶式爆品矩陣”是朝雲集團業績增長的核心驅動力，內在邏輯是公司産品創新能力持續增强。朝雲集團持續進行産品開發和升級，打造了多款强功效性、成分健康、體驗感好、顔值高的大單品，實現産品結構優化幷提升高利潤率産品占比。根據NielsenIQ零售市場數據，朝雲集團的殺蟲驅蚊産品連續十年（2015年－2024年）在中國同類産品中的綜合市場份額排名第一。在新爆品和高複購驅動下，今年上半年，家居護理産品類別收入11.64億元，同比增長11.5%。可以預見，隨著健康與品質生活理念的普及，高品質産品將持續推動朝雲集團業績高質量可持續穩利潤增長。與此同時，公司還憑藉前瞻性市場布局和資源整合能力，從家居護理和個人護理領域向高潜力的寵物護理領域擴張，用强者恒强的邏輯書寫新的篇章。二、“它經濟”的新增長極成了以家清品類作為基本盤且保持穩利潤、可持續發展的朝雲集團，在寵物賽道的布局上也被市場視爲未來增長的重要勢能。而從這份中報看，公司逐漸將這股勢能成功轉化為動能。朝雲集團通過打造人寵互動休閑娛樂的治愈系消費新場所，主打購物中心及生活社區消費業態。公司旗下擁有爪爪喵星球及米樂乖乖寵物生活館兩大實體寵物店品牌，自去年3月開始，展開火速開店模式，截至今年6月30日，已在全國6大城市開設46家門店，遍布深圳、上海、成都、杭州、蘇州、重慶等地。同時，為更符合當下年輕消費群體的審美需求，在集團品牌團隊的支持下，成功完成了寵物門店改造，品牌形象更加突出，更易于被消費者接受，提升了年輕消費群體的覆蓋率。據瞭解，改造後門店收入同比增長233%。中金公司發布研報指出，朝雲集團寵物賽道雙位數擴容可期。公司拓展寵物實體服務業態，成功建立寵物業務護城河。寵物業務與家居清潔、個人護理兩大業務板塊交相輝映，打造了朝雲集團高質量穩增長的多引擎。三、發展潜力兌現，多品牌多品類布局成就全渠道高增長受益于核心業務板塊的成長，朝雲集團實現了新電商渠道高質量穩利潤發展和綫下渠道提質擴容的幷行。今年上半年，綫下實現營收8.43億元，同比增長6.5%；綫上實現營業收入4.06億元，同比增長18.9%。這也說明朝雲集團全渠道發展戰略正在兌現潜力。尤為值得關注的是，公司新電商渠道增勢亮眼。以抖音為例，朝雲集團打造了 “超威驅蚊小綠瓶”等億元單品，長期占據平臺品類各榜單首位，新電商增幅達到300%。未來，以多品牌多品類全渠道的長期增長為方向，朝雲集團有望成為消費品板塊獨特的Alpha。四、業績增速與派息“雙高”，港股投資者的“夢中情司”？綜合上述分析，在消費品板塊衆多公司中，朝雲集團構築起好技術、好産品、好渠道的業務壁壘，形成了同行難以複製的競爭優勢。這一優勢保證了朝雲集團能同時實現高增長、穩利潤和持續高額派息。因此，公司契合了成長投資和價值投資兩種市場風格的特點，完美符合巴菲特曾提出的“成長和價值本是同根生”。我們預計，朝雲集團投資者有望獲得較强的收益確定性。一方面，港股高股息資産長期效益顯著，根據《證券市場周刊》統計，配置港股高股息資産隨著時間的拉長獲得投資回報的概率呈現規律性和顯著性；另一方面，港股市場深度調整後，估值水平已處于歷史相對低位，朝雲集團亦形成“估值窪地”，資産性價比愈發凸顯。可以預見，隨著業績高增長與高派息策略延續，像朝雲集團這樣持續高派息的公司將繼續領跑行業。 Copyright 2024 亞太商訊 via SeaPRwire.com.

香港, 2024年8月30日 - (亞太商訊 via SeaPRwire.com) — 2024年8月28日，復星國際（HKEX: 0656）公佈2024年中期業績。報告期內，總收入保持增長，達人民幣978.4億元；產業運營利潤保持增長，達人民幣34.7億元，歸母淨利潤為人民幣7.2億元。復星國際董事長郭廣昌在29日上午的業績發佈會上表示，「上半年，儘管宏觀環境充滿挑戰，我們堅定執行聚焦主業戰略，圍繞形成優勢的產業賽道，打造行業數一數二的好公司、好產品，總體來看卓有成效。我們將持續聚焦創新、聚焦全球化，同時注重輕資產運營，以具備競爭優勢的核心能力驅動長遠發展。」今年以來，國內經濟恢復不穩固，國際市場持續波動，讓包括復星在內的中國企業面臨諸多挑戰。復星持續推進戰略聚焦，以核心能力驅動企業發展，實現核心產業提質增效，資產底盤保持穩健。分析人士認為，從復星中期業績報告釋放的信息來看，復星聚焦家庭消費核心產業，先人一步推進創新和全球化，這一戰略持續為復星夯實業務底盤，帶來可預期的穩定贏利；同時，這兩年復星積極推進輕資產運營，優化資產組合，持續降低桿杆，現金儲備充裕，財務安全墊日漸厚實，有望推動市場對復星的價值進行重估。全球化和創新「先人一步」，打造「數一數二」的企業和產品      今年上半年，復星四大核心子公司——復星醫藥、豫園股份、復星葡萄牙保險、復星旅文，總收入達人民幣721.7億元，佔集團總收入的比重達到74%。復星聚焦主業的效果進一步顯現，其在醫藥、旅遊、消費、保險等核心產業賽道的優勢持續提升。在上述核心賽道，通過多年努力，復星已打造出多個在行業排名前列的「數一數二」的企業和產品。例如，復星醫藥位列中國醫藥工業百強第二名，今年上半年也連續第三年入選全球藥企管線規模前二十強；復宏漢霖是首個在港股贏利的中國創新生物製藥公司，旗下多款自主開發的單抗生物類似藥，引領中國生物醫藥行業快速發展，首款重磅產品漢利康是首個獲批上市的國產生物類似藥；復星葡萄牙保險在葡萄牙保險市場市佔率保持第一，在全球葡語區保險市場居前列；智造板塊的翌耀科技是全球領先的自動化和數字化企業。此外在快樂業務板塊，復星旅文旗下Club Med是精緻「一價全包」度假的全球領導者；三亞亞特蘭蒂斯是國內領先的高端綜合度假旅遊目的地，推動海南旅遊進入3.0時代；豫園旗下老廟黃金，是中華老字號，更是享譽全國的珠寶品牌。這些在各自行業「數一數二」的企業和產品，幫助復星持續鞏固在相關產業的領導地位。對復星而言，穩健贏利的增長來自兩個方面，一是創新，一是全球化。在當前國內經濟「內捲」的大環境下，「出海」成為企業界的「必答題」。但復星早在2007年便啟動全球化征程，在海外摸爬滾打17年，今天已成為植根中國的標杆性的全球化企業之一、在全球超過35個國家和地區擁有深度產業佈局。17年出海征程裡，復星捕獲了很多成功的項目，也遇過很多挑戰，最重要的意義在於鍛造了國內企業稀缺的全球化能力，並在全球打通不同市場、不同業態和資源，實現了全球佈局、全球運營和全球發展，全球化深度運營能力持續提升。有一組數據非常能闡釋情況，2024年上半年，集團海外收入達人民幣458.7億元，同比增長4%，佔總收入的比重上升至47%，近半收入來自海外，這在中國企業中並不多見。更重要的是，復星在全球化過程中積極推進旗下企業生態賦能與協同，旗下海內外成員企業在全球化研發、業務拓展、運營及投融資等方面取得多項進展。上半年，復星旗下企業的生物藥出海再獲突破。復星旗下的復宏漢霖，自主開發的漢曲優獲得美國食品藥品監督管理局批准上市，成為在中國、歐盟、美國獲批的「中國籍」單抗生物類似藥；中國首個生物類似藥漢利康獲得秘魯藥監局批准上市，成為繼漢曲優和漢斯狀後，復宏漢霖第三款海外獲批上市的自研藥品。再如復星旅文Club Med地中海俱樂部在全球運營67家度假村，2024年上半年營業額再創新高，達人民幣88.9億元，同比增長10.3%。其中，歐非中東及美洲區持續增長，亞太區復蘇顯著。2024年5月，Club Med 在阿曼簽約中東首個度假村。復星葡萄牙保險，從葡萄牙出發積極拓展海外市場，今年上半年取得葡萄牙境內和國際業務雙增長，海外業績佔比進一步提升，國際業務錄得總保費歐元8.85億元，佔比超過30%；國際業務淨利潤約歐元0.51億元，佔比超過40%。復星旗下全球領先的自動化和數字化企業翌耀科技，也在靜悄悄推進海外拓展，2024年上半年海外新增訂單達到人民幣39.9億元，其中美國市場訂單大幅增加，新增訂單達到人民幣7.5億元，同比增長超過一倍。創新同樣是復星長期積累並始終堅持的核心能力。報告期內，復星持續深化科技與創新能力，創新投入達人民幣35億元；全球視野下的整合式創新模式更加成熟，一批突破性成果正持續為復星帶來穩健贏利，成為復星的增長動力。從創新藥研發方面來看，復星醫藥共有4個產品共9項適應症獲批上市，4個產品共9項適應症進入上市前審批/關鍵臨床階段，9項產品（按適應症計算）獲批開展臨床試驗。復宏漢霖自主研發並生產的創新生物藥不斷取得突破性進展，全球首個一線治療小細胞肺癌的抗PD-1單抗漢斯狀已獲批4項適應症，累計惠及患者超7.5萬，對外授權覆蓋美國、歐洲、東南亞、中東和北非等70多個國家和地區。此外，新一代口服血小板生成素受體激動劑（TPO-RA）蘇可欣新適應症也獲得國家藥監局批准。尖端醫療器械及創新療法的佈局也取得新進展。2024年6月，直觀復星總部產業基地在上海啟用，是直觀醫療在亞太地區最大的研發、生產和培訓一體化基地，達芬奇手術機器人國產化顯著提速。直觀復星Ion支氣管導航操作控制系統也於2024年3月通過國家藥監局批准，並於7月上市。       「輕資產運營」打法成型，價值重估可期得益於業務面的堅實支撐，復星財務面也持續改善。報告期內，復星持續優化資產組合，降低桿杆，財務狀況保持穩健。截至報告期末，集團調整後總債務佔總資本比率為50.2%，維持了2020年以來的下降趨勢；調整後NAV為每股港幣17.4元，顯示當前復星國際股價被嚴重低估。復星也在積極夯實財務安全墊，保持充裕的現金儲備。這次報告期內，復星國際現金、銀行結餘及定期存款達到人民幣1095.5億元，較2023年底增加人民幣約171億元。上市17年來，累計分紅港幣256億元，分紅率逐漸提升，近五年分紅率在20%及以上。就在 2024年6月，國際評級機構標普也充分肯定復星財務戰略成效，確認評級展望為「穩定」。在通過持續的創新和全球化實現穩定贏利的同時，復星面對新的市場環境，也繼續推進「瘦身健體」，陸續退出一些非核心產業，同時積極推進「輕資產運營」，打法也逐漸成型。2024年5月，復星出售德國私人銀行HAL 99.74%股份，引起市場關注，交易完成後，復星將不再持有HAL股份，但全額保留HAFS基金服務業務，以輕資產運營模式，管理約千億歐元資產。在文旅賽道，復星的輕資產運營模式成效顯著，Club Med、三亞亞特蘭蒂斯、太倉阿爾卑斯等IP成為國內旅遊行業標杆。報告期內，Club Med採用租賃及管理模式的度假村佔比為85%，自持度假村佔比降至15%。2024年4月，復星旅文在麗江地中海國際度假區打造的全新IP——阿美澤雪山營地對外開放後，迅速火爆「出圈」，帶動度假區內Club Med麗江度假村與麗江地中海棠岸度假酒店入住率顯著提升。2024年6月，復星旅文還攜手太倉市政府共同打造一站式冰雪主題旅遊度假目的地太倉阿爾卑斯國際度假區二期。該項目總投資超人民幣50億元，由太倉市政府平台出資打造，由復星旅文運營管理。此前復星旅文對阿爾卑斯雪世界的成功運營，為二期項目提供了信心和動力，該項目有望打造多項「世界雪場之最」。與此同時，復星攜手合作夥伴打造了一批產業基金，深度佈局優勢產業。2024年3月，復星醫藥依託在生物醫藥領域的領先優勢，聯手深圳市引導基金等其他七方投資人，共同出資設立人民幣50億元生物醫藥產業基金，募集資金全部投資於生物醫藥、細胞和基因等領域。復星醫藥旗下復健資本通過深圳市公開遴選中標，獨家管理該基金。4月，深圳市政府與復星簽署戰略合作框架協議，雙方集聚優質創新資源，進一步加強在生物醫藥、文體旅遊、時尚消費等領域的合作。也是在2024年4月，復星創富聯合武創投、武漢基金，設立人民幣30億元產業基金，首期規模人民幣11億元。這是湖北省設立人民幣200億元政府引導基金以來，第一隻出資的市場化基金，主要聚焦新一代信息技術、雙碳、智能製造、大消費四大賽道。面對當前的市場環境，可以預計，未來復星仍將積極推進輕資產運營，持續擴大「朋友圈」，加強與各方深度合作，通過優勢互補，實現共贏。多位市場分析人士認為，復星通過創新和全球化的核心戰略，推動業務實現持續穩定盈利，通過退出非核心產業、輕資產運營，持續降債等措施，保持財務面的穩健，有望推動市場對復星的價值重估。郭廣昌認為，未來投資者會更加看重核心產業增長和現金流的穩健，「一次性的資產出售都是短期的，核心業務的成長，才是企業穩健贏利的核心因素」，復星希望打造一個聚焦核心產業的家庭消費產業集團，產業的發展和贏利更可預期。無論是集團層面還是每一塊業務，都要給客戶、投資人提供風險可控、能穩健成長的企業價值。 Copyright 2024 亞太商訊 via SeaPRwire.com.

- 全球首創新藥雙功能葡萄糖激酶激活劑（GKA）多格列艾汀（商品名：華堂寧®）于2023年底成功納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》（“國家醫保藥品目錄”）。華領醫藥與商業化合作夥伴拜耳以及80家一級經銷商共同推動多格列艾汀的商業化，開始進入中國31個省級醫藥市場。- 2024年1月1日新版“國家醫保藥品目錄”正式執行，2024年上半年，多格列艾汀的銷售量顯著增加。截至2024年6月30日，共銷售84.6萬盒，實現銷售收入人民幣1.027億元，相比2023年6月30日，同比增長46%。- 得益于政府支持創新藥品的市場准入政策，多格列艾汀加速進入上海、北京和天津等地醫院。截至2024年6月30日，已有2100多家醫院和2900多家藥店開始了多格列艾汀的處方銷售。多格列艾汀在醫院、藥店和網絡藥店銷售的比例分別為72%、20%和8%。- 2024年上半年，公司毛利約為4780萬元，毛利率為46.5%。截至2024年6月30日，公司銀行結餘及現金約13.388億元，相比2023年6月30日，同比增長51.9%。- 多格列艾汀的生産能力繼續擴大，預計2024年産能將達到300萬盒以上，公司已經與合作夥伴建立了更大産能的新工藝，正在接受生産許可部門的監管審查。- 上市後臨床研究加速進行，其中HMM0601研究已入組1368例患者，該研究旨在通過收集2000例2型糖尿病患者1年的臨床安全性數據來評估多格列艾汀的長期安全性。HMM0701研究已入組102例患者，該研究是一項前瞻性真實世界研究，旨在探索多格列艾汀在改善血糖穩態、認知功能和糖尿病緩解方面的臨床獲益。自2022年10月上市銷售以來，過去20個月約有10萬名患者使用多格列艾汀，藥物安全性良好。- 公司與中國香港臨床研究人員合作開展了兩項孟德爾隨機化研究，結果顯示，激活葡萄糖激酶（GK）在降低心血管疾病風險和血脂异常風險方面具有長期獲益性，研究結果已經發表在《心血管糖尿病學》雜志上。公司將携手商業化合作夥伴進一步探索多格列艾汀更加廣泛的臨床適應症。香港, 2024年8月30日 - (亞太商訊 via SeaPRwire.com) — 華領醫藥（“公司”，香港聯交所股份代號：2552）宣布公司及其附屬公司截至2024年6月30日止，6個月（“報告期”）未經審核的綜合業績，以及公司上半年業務進展和未來業務展望。華領醫藥創始人、首席執行官陳力博士表示：“2024年上半年是華領醫藥商業化進程的又一個里程碑。多格列艾汀成功納入國家醫保藥品目錄，大大提升了患者用藥的可及性和可負擔性。在國家和各級政府全鏈條支持生物醫藥産業發展的背景下，在公司與商業化夥伴和生産夥伴的共同努力下，多格列艾汀正迅速提升産能，加速進入全國各地的醫院和藥房，以惠及更多患者。隨著用藥人數的持續增長，多格列艾汀的安全性得到了良好的驗證，其經濟效益和社會效益也大幅提升，為公司未來發展注入了信心。通過銷售擴張和優化運營，我們希望能够在2025年實現公司盈利。目前，華領醫藥還正在全球範圍內開展多格列艾汀的基礎研究和臨床研究，希望不斷拓展多格列艾汀的適應症和適用人群，探索更加廣泛的疾病應用領域，造福不同的患者人群。”臨床研究和公司運營進展摘要- 進入國家醫保藥品目錄後，多格列艾汀速進入醫院和藥店，尤其在上海、北京、天津等城市，政府推出了支持創新藥進入市場的政策。截至2024年上半年，多格列艾汀已經進入全國2100多家醫院。- 上半年，多格列艾汀實現銷售收入人民幣1.027億元，預計在2024年下半年將繼續增長。基于進入醫保建立的新基礎，公司正不斷與合作夥伴密切協作，優化多格列艾汀的生産流程，提高生産效率，從而擴大産能幷降低生産成本。- 公司繼續在約80家醫院開展上市後真實世界研究，增進瞭解多格列艾汀對于2型糖尿病及其幷發症（如記憶力减退、糖尿病腎病）患者的獲益。除此之外，通過與中國香港的臨床研究夥伴的合作，我們使用孟德爾隨機化(MR)研究發現激活GK可以降低心血管疾病和血脂异常風險，有助于公司通過多格列艾汀進一步瞭解GK激活的更多獲益，幷探索多格列艾汀新的適應症。孟德爾隨機化是一種統計方法，利用遺傳變异體來研究暴露（如治療）對結果（如疾病）的因果效應。MR的獨特優勢在于它比傳統的觀察性研究更不容易受到混雜因素和時間相關偏倚的影響，因此在循證醫學中，當隨機對照試驗不可實施時，MR被視為最高循證醫學證據。- 公司正在積極推進針對2型糖尿病患者的上市後真實世界研究，包括在中國內地的HMM0601研究和HMM0701研究，以及在中國香港的HMM0123研究。在這些研究中，公司正不斷積累多格列艾汀單獨用藥，以及多格列艾汀與二甲雙胍、DPP-4抑制劑、SGLT-2抑制劑、GLP-1RA和胰島素等聯合用藥的臨床數據，以優化血糖穩態治療的臨床證據，幷且為多格列艾汀拓展在糖尿病預防和緩解等方面的適應症提供新的證據。- 公司正在持續豐富藥物開發管綫，尤其是固定複方製劑的開發。多格列艾汀-二甲雙胍固定複方劑量已經進入生産工藝驗證階段，公司預計將于2028年推出2型糖尿病治療的新藥。未來，公司將開發更多的多格列艾汀固定複方製劑新藥用于糖尿病及其幷發症，如肥胖、糖尿病腎病等的個性化治療。- 為了進一步發揮多格列艾汀在修復伴有肥胖的糖尿病患者的GLP-1分泌方面的獨特優勢，公司在美國啓動了第二代GKA的1期臨床研究。目前，試驗進展順利，在3組2型糖尿病患者中完成了劑量遞增。公司預計在2024年第四季度發布頂綫數據，以支持未來的藥物開發。- 在2024年美國糖尿病協會（ADA）科學年會上，公司報告了多項基礎研究和臨床研究進展。一項研究顯示，多格列艾汀聯合SGLT-2抑制劑可以改善血糖控制，聯用效果優于兩者單獨用藥，幷且提示多格列艾汀有望在新的適應症中發揮作用，用于與SGLT-2抑制劑恩格列淨等慢性腎病治療藥物聯合用藥，治療中晚期糖尿病腎病患者。- 公司正在使用孟德爾隨機化研究的框架探索多格列艾汀更多的藥物使用機會，如腎病、神經病變相關疾病、眼部相關疾病、認知障礙和癌症等。公司將進一步利用動物研究驗證更多可能的機遇。- 公司將持續優化蛋白變構調節技術，幷積極擴展應用領域，推進負向變構調節劑在GK和GPCR蛋白上的應用。目前葡萄糖激負向變構調節劑已經進入臨床前藥物候選階段，作為先天性高胰島素血症和潜在的血脂异常症的臨床候選藥物。公司將繼續推進mGLUR5 NAM項目在帕金森病（PDLID）、脆性X染色體綜合征(FXS)和藥物成癮中的臨床潜力。財務摘要截至2024年6月30日止，-  公司銀行結餘及現金約13.388億元-  銷售收入約為人民幣1.027億元，共銷售84.6萬盒華堂寧®-  其他收入約為5510萬元，其中拜耳里程碑收益攤銷約4780萬元-  開支總額約2.459億元，其中研發開支約1.198億元前瞻性聲明本文包含有關華領醫藥以及産品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，于作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情况，我們幷無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文幷理解，由于各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差异。關于華領華領醫藥是一家總部位于中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注于未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥彙聚全球醫藥行業高素質人才，融合全球創新技術，依托全球優勢資源，研究開發突破性的技術和産品，引領全球糖尿病醫療創新。公司核心産品華堂寧®（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，華堂寧®已獲得中國國家藥品監督管理局（NMPA）的上市批准，用于單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對于腎功能不全患者，無需調整劑量，是一款可用于不同程度的腎功能損傷（包括未進行透析的終末期腎損）的2型糖尿病患者的口服降糖藥物。華領醫藥將與領軍企業拜耳共同推動華堂寧®在中國的商業化推廣，以造福糖尿病患者及其家庭。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com新聞免責聲明本材料，如爲上下文論述的準確性和完整性，提及在中國上市的産品相關信息的，特別是標識或要求，應遵循中國監管機構批准的相關文件。另外，相關信息不應被解讀爲對任何藥物或者診療方案的推薦或者宣傳，亦不應替代任何醫療衛生專業人士的醫療建議，涉及醫療的相關事宜務必諮詢醫療衛生專業人士。 Copyright 2024 亞太商訊 via SeaPRwire.com.